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 Arguably the causative agent of Alzheimer's disease (AD), amyloid beta (A)-
peptides, are generated by sequential proteolysis of the amyloid precursor protein 
(APP) by  and secretase activities. Alternatively, APP can be processed non-
amyloidogenically by an -secretase activity that cleaves within the A-domain, 
precluding the formation of intact A-peptides and liberating a neuroprotective 
fragment, sAPP. This latter proteolytic event is catalysed by a disintegrin and 
metalloproteinase (ADAM) 10. 
 Recent research has suggested that glucagon-like peptide-1 (GLP-1) 
analogues; Lixisenatide, Dulaglutide, Liraglutide, and Exenatide (Exendin-4), currently 
used to treat diabetes, may also be beneficial in the treatment of neurodegenerative 
conditions such as AD, as they have been shown to exert neuroprotective properties. 
Research has also suggested that one of these compounds, exendin-4, can enhance 
the amount of membrane-associated ADAM10.  
 The current study, therefore, aims to determine firstly; whether GLP-1 
analogues can protect neuroblastoma, SH-SY5Y cells, against chemical stressors of 
relevance to AD and, secondly, whether these compounds alter ADAM10 
maturation/activity and the proteolysis of the enzyme's substrates, APP, prion 
protein (PrP) and neuroligin1 (NLGN-1). Cells treated with hydrogen peroxide (as an 
oxidative stressor), cobalt chloride (as a hypoxic mimic), methylglyoxal (MG) or 
thapsigargin (TG) (as Endoplasmic Reticulum stressors) were co-treated with or 
without GLP-1 analogues and cell viability was subsequently monitored along with 
the expression and proteolysis of ADAM10 and its substrates. The results of the 
study showed that the GLP-1 analogue, liraglutide, had no major effect in terms of 
protecting SH-SY5Y cells against any of the afore-mentioned chemical stressors. 
However, a second compound, exendin-4, was protective against TG-induced 
cytotoxicity. Thapsigargin impaired the proteolytic maturation of ADAM10 suggesting 
a decrease in the activity of the enzyme but exendin-4 was unable to reverse this 
effect. Nonetheless, exendin-4 was able to partly reverse the inhibitory effect of TG 
on the expression of endogenous APP, and shedding of over-expressed NLGN1, and 
sAPP in cells over-expressing APP695. Interestingly, TG caused an increase in 
expression of APP695, and an intracellular accumulation of PrP and, subsequently, did 
not alter the cell surface ADAM-mediated shedding of this protein.  
 Collectively, these data indicate that liraglutide was ineffective in the 
protection of SH-SY5Y cells against the chemical stressors employed. However, 
exendin-4, is mildly protective against thapsigargin-mediated oxidative stress and is 
able to partly restore the TG-induced decrease in expression of endogenous APP, and 
 shedding of APP695 and NLGN1. Unusually though, this latter effect was not 
associated with restored proteolytic maturation of ADAM10. 




























ACh - Acetylcholine 
AD – Alzheimer’s Disease 
AICD – APP Intracellular Domain 
APP – Amyloid Precursor Protein 
ADAM10 – A Disintegrin And Metalloproteinase 10  
BACE1 – -site amyloid precursor protein cleaving enzyme 1 
ChAT – Choline Acetyltransferase 
CoCl2 – Cobalt Chloride 
ER – Endoplasmic Reticulum 
GLP-1 – Glucagon-Like Peptide-1  
H2O2 – Hydrogen Peroxide 
IDE – Insulin Degrading Enzyme 
MG – Methylglyoxal 
NFTs – Neurofibrillary tangles 
NLGN1 – Neuroligin-1 
NMDA – N-Methyl-D-Aspartate 
OS – Oxidative Stress 
PHFs – Paired Helical Filaments 
PrP – Prion Protein 
PS1/PS2 – Presenilin-1/Presenilin-2 
sAPP- soluble APP alpha 
sAPP – soluble APP beta 
TG – Thapsigargin 
TSEs – Transmissible Spongiform Encephalopathies 
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 The purpose of the current study was to characterise the neuroprotective 
effects of a group of diabetes drugs, known as glucagon-like peptide-1 (GLP-1) 
analogues, against stress-inducing agents relevant to the neurodegenerative 
condition, Alzheimer's disease (AD). In addition, the study attempted to determine 
whether GLP-1 analogues might exert their cytoprotective effects by altering the 
processing of substrates of the enzyme, a disintegrin and metalloprotease 10 
(ADAM10), particularly the amyloid precursor protein (APP), which has direct 
relevance to the pathogenesis of AD. 
 
1.2. Alzheimer’s disease. 
 Dementia is a term used to describe a set of symptoms associated with 
cognitive impairment and degeneration of the brain (nhs.uk, 2018). Alzheimer’s 
disease was first described in 1906, by Alois Alzheimer. It is the most common cause 
of dementia and  can be a consequence of brain tissue atrophy causing symptoms 
such as memory loss, speech impairment and aggression (nhs.uk, 2018) AD is a 
progressive degenerative disease, meaning symptoms worsen over time with no 
prospect of reversal, dictating a poor prognosis for AD patients. 
 
1.2.1. Onset of Alzheimer’s Disease. 
 Depending on the age of the patient at the time of onset, AD can be classified 
into two categories; sporadic and familial (SAD and FAD). Sporadic AD tends to occur 
over the age of 60-65 years and is caused by a combination of environmental and 
genetic risk factors. Whilst SAD represents some 95% of all cases (Bali et al., 2012), 






 Dementia affects approximately 5% of the global population and has been 
recognised by the World Health Organisation (WHO) as a public health priority 
(World Health Organization, 2016). The WHO estimated that 60-70% of all dementia 
cases could be caused by Alzheimer’s disease. The region with the highest absolute 
number of dementia sufferers is Asia but the regions with the highest disease 
prevalence are the Americas and Europe, with 6.4% and 5.9% prevalence, 
respectively (Prince et al., 2015; Table 1.1.). However, the same report shows that 
the projected number of cases in Europe by 2050 increases at a lower rate than in 
other regions, with numbers in Africa estimated to rise by around 300%. This is most 
likely the result of anticipated economic growth and improved healthcare in 
developing countries leading to a higher life expectancy and an associated increase in 
the prevalence of dementia in this more aged population. The study also predicts 
that there will be 9.9 million new cases of dementia per year, which equates to the 
development of a new case every 3.2 seconds. The WHO lists Alzheimer’s disease 
and other similar dementias, collectively, as the seventh leading cause of death in 
upper-middle income economies (19.5% of total deaths) and the third leading cause 




Table 1.1. The number and prevalence of dementia cases and predicted increases in case numbers in 
different regions of the world. Data adapted from source (Prince et al., 2015). 
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 A report from the Alzheimer’s Association claimed that there are 
approximately 476,000 new cases of the disease per year. It stated that roughly 1 in 
9 people aged over 65 and 1 in 3 people over 85 years old have AD, and that two 
thirds of the people with the condition in America are women (Alzheimer's 
Association, 2016). 
 Further studies have suggested that the number of dementia cases can also 
differ between ethnicities. Meyeda et al. (2016) reported that the incidence of 
dementia in America was highest in African Americans and Native Americans with 
Latinos, Pacific Islanders and Whites having a mid-range incidence and Asian-
Americans displaying the lowest incidence. The results suggested that African 
Americans were the most at risk of developing Dementia in the next 25 years, with a 
cumulative incidence of 38%. 
 
1.2.3.  Current treatments. 
 There are currently four main drug treatments for AD available commercially; 
donepezil, galantamine, rivastigmine, and memantine. The first three drugs are 
acetylcholinesterase inhibitors and work by reducing the amount of acetylcholine 
degradation by acetylcholinesterase. The fourth is an N-methyl-D-aspartate (NMDA) 
receptor antagonist that targets glutamatergic transmission and, consequently, the 
exposure of cells to calcium (Alzheimer's Association, 2017). However, all of these 
treatments are only able to alleviate the symptoms of the disease; they cannot cure 
or prevent its onset. Drugs and therapies that could potentially do this are known as 
‘disease-modifying’ as they aim to either stop or alter the progression (Yiannopoulou 
& Papageorgiou, 2012). Many of these drugs are currently in clinical trials and target 
proposed earlier stages of the disease, such as the formation of neurofibrillary 
tangles and the generation of amyloid-beta (A peptides. Various other therapies 
have also been tested including vaccinations, and drugs targeting risk factors such as 





 Currently, there is no cure for AD, mainly due to the large amount of 
uncertainty and ambiguity regarding the cause of the disease. A common theory is 
that AD is a multifactorial disease and can have a plethora of causations. There are 
many hypotheses associated with this disease, including but not limited to; 
inflammatory, mitochondrial, vascular, oxidative stress, and cholesterol (Mohandas, 
Rajmohan and Raghunath, 2009).  However, arguably the three  best known 
hypotheses for the causation of AD are outlined in the next section of this study. 
 
1.3. Biochemical causation of Alzheimer’s Disease.  
1.3.1.  The cholinergic hypothesis. 
 The cholinergic hypothesis as a potential cause of AD was first introduced by 
Bowen et al. (1976) and is the oldest theory. It suggests that a reduction in choline 
acetyltransferase (ChAT) activity (the enzyme responsible for combining acetyl-CoA 
and choline) leads to decreased production of acetylcholine (ACh), which 
consequently results in a reduction of neurotransmission between neurons. Brown et 
al. (1977) demonstrated a decrease in ChAT in approximately 66% of autopsy and 
biopsy cortical specimens from AD sufferers. The resultant lack of cholinergic 
signalling is thought to have an effect on the rapid decline of cognitive ability in AD 
patients. However this theory has been challenged as it has been suggested that a 
decline in cholinergic activity in the cortex  can be caused by ageing (Smith et al., 
1999) and therefore does not necessarily indicate the onset of AD.  In addition, 
reduced levels of cholinergic molecules are evident in other neurodegenerative 
diseases such as Parkinson’s disease (Perry et al., 1985). Furthermore, it has been 
shown that ChAT seems only to be reduced in later stages of the disease (Davis et al., 





1.3.2.  The neurofibrillary tangle (Tau) hypothesis. 
 Microtubules play an integral role in the stability of neuronal structure and 
are particularly significant in axonal and dendritic development in addition to being a 
key component in molecular transportation and signalling (Baas et al., 2016). 
Microtubules consist of two isoforms of tubulin, and tubulin, that are coupled 
together to form heterodimers which, in turn, combine to form protofilaments. The 
latter then combine to form the mature microtubules. Conformational stability of 
microtubules is maintained through the association of phosphorylated Tau protein 
binding with tubulin. Tau has six isoforms, all of which are found in the adult brain 
(Goedert et al., 1989). In Alzheimer’s disease and other tauopathies, Tau becomes 
hyperphosphorylated resulting in the aggregation of Tau monomers to form paired 
helical filaments (PHFs) (Grundke-Iqbal et al., 1986). In healthy adult brain, 
approximately 5% of Tau is phosphorylated; this figure rises to 100% of the protein in 
PHFs (Weidner et al., 2009). The accumulation of PHFs eventually creates 
neurofibrillary tangles (NFTs); insoluble structures commonly found in the brains of 
AD patients (Kosik, Joachim and Selkoe, 1986). The formation of NFTs has a 
detrimental effect on the structure of microtubules and, consequently, on neuronal 
development and signalling (Alonso et al., 1994). In particular, impaired calcium 
signalling, often mediated by NFTs, is believed to be related to the short term 
memory loss characteristic of AD (Green, Smith, and Laferla F., 2007). 
 
1.3.3.  The amyloid cascade hypothesis. 
  Arguably the most well-known theory as to the biochemical causation of AD 
is based around the proteolysis of the amyloid precursor protein (APP) and the 
subsequent aggregation of amyloid-beta (A)-peptides in the brain. Furthermore, it 
is possible that A-peptide accumulation links the three main causation hypotheses, 
with suggestions that A-peptide accumulation reduces choline uptake and ACh 
release (Francis et al., 1999) and also interferes with the phosphorylation of Tau 
(Stoothoff & Johnson, 2005). As such, the amyloid cascade hypothesis suggests that 
the altered proteolysis of APP could be the origin of AD, with a subsequent cascade 
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of events including the formation of NFTs and reduced neurotransmission resulting 
in the onset of AD.  
 
1.4. Amyloid precursor protein.  
 The amyloid precursor protein (APP) is a Type I membrane protein that is 
coded for by the APP gene located on chromosome 21 in humans (Omim.org, 2017). 
APP contains 19 exons (Yoshikai et al., 1991) and alternate splicing produces various 
isoforms of the APP protein. There are three main isoforms, APP695, APP751, and 
APP770. APP695 is the most abundant isoform in the brain (Zheng & Koo, 2011) with 
the three isoforms being present at a ratio of 20:10:1, respectively, in the brain 
cortex (Nalivaeva & Turner, 2013). As a result of alternate splicing, APP751 contains an 
extra domain known as the Kunitz-type protease inhibitor (KPI) domain and APP770 
contains both the KPI domain and an OX-2 domain whereas APP695 contains neither 
of these two domains. 
 The APP protein comprises of a large extracellular region, a short membrane-
spanning region and a cytoplasmic domain (Fig. 1.1.). The extracellular region 
contains the E1 and E2 domains, the former of which can be subdivided into a 
growth factor-like domain (GFLD) and a copper binding domain (CuBD). C-terminal to 
the CuBD are the extension domain (ED) and an acidic domain (AcD) the latter of 
which is made up of 56% acidic amino acids (Coburger et al., 2013). The E2 domain, 
also known as the central APP domain (CAPPD), contains the RERMS sequence 
thought to have a role in mediating the trophic properties of APP (Reinhard et al., 
2005). The juxtamembrane region (JMR) connects the E2 domain to the 
transmembrane helix located in the plasma membrane which, in turn, links the 
extracellular region to the APP intracellular domain (AICD). 
 APP is post-translationally subject to N-glycosylation, O-glycosylation and 














occurs in lysosomes due to a YENPTY sequence in the AICD, which-+ encodes a signal 
promoting endocytosis (El Ayadi et al., 2012). The remaining APP is subject to 
proteolysis by , , and -secretases (section 1.5.). 
 Although APP is ubiquitously expressed in the human body, it is particularly 
abundant in the brain. Whilst the exact physiological function of the protein remains 
unclear, APP could play a role as a cell surface receptor, displaying similarities to 
Notch (Zheng & Koo, 2011) or in the regulation of cell adhesion (Reinhard et al., 
2005). Specific APP domains have also been associated with neurotrophic and 
synaptotrophic properties (Thinakaran & Koo, 2008). 
 
1.5. APP proteolysis.  
 As previously mentioned, full-length APP can be subject to proteolytic 
processing by -, - and -secretases and the secretases by which the protein is 
Figure 1.1. The structure of amyloid precursor protein (Coburger et al., 2013). 
Need  Need abbreviations  
 9 
 
processed determine whether the toxic A-peptides associated with AD causation 
are formed. 
 
1.5.1.  The amyloidogenic pathway. 
 The cleavage of full-length APP by the - and a -secretases constitutes the 
amyloidogenic proteolytic pathway. The -secretase, BACE1 (-site amyloid 
precursor protein cleaving enzyme 1), is a type-I integral membrane glycoprotein 
(Venugopal et al., 2008) that is synthesised in the endoplasmic reticulum (ER) and 
matures into an active enzyme through the Golgi (Chow et al., 2009). The enzyme 
cleaves full-length APP into two fragments; soluble APPbeta (sAPP and a 
membrane-associated C-terminal fragment (C99) (Fig. 1.2.).  Several studies have 
suggested possible cellular locations for this cleavage, with evidence of some 
processing occurring at the cell surface (Chyung & Selkoe, 2003). However, the 
consensus is that BACE1 has a preference for an acidic environment and that 
cleavage occurs following re-internalisation into endosomal compartments 
(Venugopal et al., 2008). The biological function of the sAPP fragment generated is 
not clear, although it is has been suggested that it may boast some neurotrophic 
properties (Chasseigneaux et al., 2011). 
 -secretase is a multi-protein complex consisting of presenilins (presenilin-1 
(PS1) or presenilin-2 (PS2)), nicastrin, anterior pharynx defective 1 (APH-1), and 
presenilin enhancer 2 (PEN-2) (Chow et al., 2009). The proteolytic ability of this 
secretase derives from the aspartyl proteinase activity of the presenilins, with PS1 
being the predominant form in brain (Duarte et al., 2013). The complex cleaves the 
C99 fragment within its intra-membrane domain producing the APP intracellular 
domain (AICD) and ApeptidesFig. 1.2.). Various lengths of A-peptidescan be 
formed as a consequence of the relaxed specificity of the -secretase complex, 
ranging from 38-43 amino acids (Chow et al., 2009). A1-42 is regarded as the most 














latter has a higher affinity for self-association and a faster rate of aggregation and is 
consequently more pathogenic (Hampel et al., 2010). 
 A-peptides can undergo degradation by various proteases including insulin 
degrading enzyme (IDE) and neprilysin (NEP) (Dorfman et al., 2010). However, they 
may also aggregate to form toxic oligomers, which then further aggregate to produce 
protofibrils, fibrils and, ultimately, A (senile) plaques. Once aggregated, little or no 
degradation of A-peptides can occur (Lajtha and Banik, 2011), resulting in the 
obstruction of nerve signals and, ultimately, the neuronal death observed in AD. 
 
1.5.2.  The non-amyloidogenic pathway. 
 Cleavage of APP by- and -secretases constitutes the non-amyloidogenic 
proteolytic pathway that accounts for 90% of the APP processing in healthy adult 
brains (Plácido et al., 2014). During this process, full-length APP is cleaved by -
secretase between lys16 and leu17 of the A region to produce soluble APP alpha 
(sAPPand C83 (Fig. 1.2). The latter fragment is then further cleaved by -secretase 
creating two products; AICD and p3. The majority of APP that reaches the plasma 
Figure 1.2. The proteolysis of amyloid precursor protein via the amyloidogenic and non-
amyloidogenic pathways (Salminen et al., 2013). 
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membrane is processed non-amyloidogenically with only that re-internalised into 
endosomes being subsequently cleaved by -secretase (Chow et al., 2009). However, 
it has also been suggested that -secretase cleavage can occur within intracellular 
structures such as the Golgi where it could potentially compete with -secretase 
activity (Skovronsky et al., 2000).  
 The fact that non-amyloidogenic processing precludes the formation of intact 
A-peptides has made the up-regulation of this pathway an attractive target as a 
therapy for AD (Lichtenthaler, 2010). Another benefit of the pathway is that the 
sAPP generated by -secretase has several important roles. Specifically in the brain, 
there is evidence that sAPP plays a role in neuritogenesis in chicks and mice, with 
the RERMS region believed to be involved in this function (Chasseigneaux & 
Allinquant, 2012). Furthermore, the fragment has been shown to increase the effect 
of growth factors on the number of adult neuroblasts (Caille´ et al., 2004) and to 
promote the proliferation of neuronal embryonic stem cells (Hayashi et al., 1994). In 
addition, sAPP has been shown to have a role in repairing neuronal damage in APP 
knock-out mice helping to enhance spatial learning and long term potentiation (LTP) 
(Ring et al., 2007). Finally, sAPP has been shown to be protective against 
neurotoxicity caused by glutamate, glucose deprivation, and oxidative stress induced 
by A(Chasseigneaux & Allinquant, 2012).  
 The majority of -secretase activity is associated with a family of proteolytic 
enzymes known as a disintegrin and metalloproteinases (ADAMs). Although a 
number of ADAMs have been shown to possess -secretase-like activity in vitro 
(Gough, Parr-Sturgess and Parkin, 2011), ADAM10 is thought to be the major 
physiological -secretase (Postina et al., 2004). The enzyme is a type-I 
transmembrane glycoprotein and consists of 748 amino acids in its immature form 
(Tousseyn et al., 2006). Its role is specifically as a protease rather than in cell 
adhesion as is the case for some members of the ADAM family (Tousseyn et al., 
2006). The ADAMs have a common modular domain structure and the ectodomain of 
ADAM10 specifically consists of a 19 amino acid N-terminal signal peptide followed 
by a prodomain, a zinc-binding metalloproteinase domain, a disintegrin domain, and 
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a cysteine-rich region (Tousseyn et al., 2006). However, ADAM10 differs slightly from 
other members of the ADAM family in that it lacks an epidermal growth factor-like 
domain (Lichtenthaler, 2010). At the C-terminal end of the ectodomain is a 
transmembrane (TM) domain and, finally, a cytoplasmic region. The prodomain of 
ADAM10 is removed by the action of proprotein convertases (furin and PC7) in the 
Golgi to form the catalytically active form of the enzyme (Lichtenthaler, 2010).  
 
1.6. ADAM10 substrates. 
 ADAM10 has over forty different transmembrane substrates (Noy et al., 
2015) many of which are of direct relevance to normal brain function or disease. 
However, in addition to APP, the shedding of two additional substrates will be 
examined in the current study; neuroligin-1 and the prion protein. 
 
1.6.1. Neuroligin-1. 
 Neuroligin-1 (NLGN-1) is a type-I transmembrane protein comprised of a large 
N-terminal ectodomain (consisting of an N-terminal signal peptide, a cholinesterase-
like domain and a carbohydrate attachment region), a transmembrane domain and 
an intracellular cytosolic region (Lisé & El-Husseini, 2006). It is expressed on the post-
synaptic membrane of glutamatergic excitatory neurons in contrast to NLGN-2 that is 
localised to GABAergic synapses (Suzuki et al., 2012). NLGN-1 has an extremely 
important function in cell adhesion between neurons facilitating intercellular 
communication and is also thought to have roles in neuronal morphology, 
synaptogenesis and functioning, and cell signalling (Zhang et al., 2015). Some of 
these functions are mediated through the interaction of NLGN-1 with a presynaptic 
cell adhesion protein called neurexin-1NRX-1).  NLGN-1 forms a dimer with two 
NRX-1 molecules binding to identical positions on opposite sides of the dimerised 





Figure 1.3. Association between NLGN-1 and NRX-1 at the synapse. Right: In the unbound 
state NLGN-1 exists as a dimer whereas NRX-1 is monomeric. Left: Two NRX-1 molecules  
bind to opposing sides of the NLGN-1 dimer causing conformational changes. (Www-
ssrl.slac.stanford.edu, 2018) 
 
The regular structure of NLGN-1 and NRX-1 at the synapse is displayed on the right. The 
left diagram shows the conformational change performed by NLGN-1 into a dimer, before 










 As well as binding to NRX-1NLGN-1 also binds to the glutamatergic N-
methyl-D-aspartate (NMDA) receptor via a transmembrane, PDZ-containing protein 
(PSD-95), which binds to the C-terminal tail of NLGN-1 (Song et al., 1999). Some 
studies suggest that increased glutamatergic activity is present in the early stages of 
Schizophrenia (Théberge et al., 2002). For this reason, potential therapy for the 
condition might involve the regulation of glutamatergic neuronal activity in the brain 
possibly by reducing levels of NLGN-1 expressed on the neuronal surface. Indeed, the 
over-expression of NLGN-1 on the surface of neurons has been shown to result in 
elevated levels of glutamate at both the pre- and post-synapses and, similarly, that 
proteolysis of the protein reduces glutamatergic neurotransmission (Suzuki et al., 
2012). The same study suggested that NLGN-1 is in fact cleaved from the neuronal 
membrane by ADAM10 to produce soluble NLGN-1 (sNLGN-1) and a C-terminal 
fragment, the latter of which is then cleaved by -secretase to release an intracellular 
domain. Furthermore, it was suggested that proteolysis occurs in the juxtamembrane 
stalk region of NLGN-1 at Gln680 or Gln681. 
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1.6.2. Prion protein. 
 The cellular isoform of the prion protein (PrPC) is highly abundant in adult 
neurons where it is attached to the plasma membrane via a glycosyl-
phosphatidylinositol (GPI)-anchor at the C-terminal end of the protein (Westergard 
et al., 2007). Furthermore the protein is thought to have roles in cellular protection 
against oxidative stress and apoptosis (Westergard et al., 2007). However, PrPc is also 
associated with the pathogenesis of the transmissible spongiform encephalopathies 
(TSEs), which include Creutzfeld-Jakob disease (CJD) and Kuru in humans, mad cow 
disease, and scrapie in sheep. These diseases occur when the scrapie-associated 
isoform of prion protein (PrPSc) corrupts the endogenous cellular isoform causing a 
conformational change of the latter from a predominantly -helical to 
predominantly -sheet structure (Fig. 1.4.) (Riesner, 2003). The -sheet content of 
PrPSc inhibits proteolysis of the protein as well as causing it to aggregate to form 
fibrils similar to those formed by A-peptides (Prusiner et al., 1983). Additionally, 
Parkin et al. showed that PrPc can be cleaved by a zinc metalloprotease, in a similar 
mechanism to that of APP (Parkin et al., 2004).  It is thought that the 
neurodegeneration observed in the TSEs is caused either by the detrimental effects 
of PrPSc blocking neuronal signalling or the reduced neurotrophic properties of 
corrupted PrPC. 
PrPc is subject to cleavage from the membrane by both phospholipase and 
ADAM activities with the ADAM-cleaved form having a size very close to that of the 
membrane-associated form suggesting that this proteolytic event occurred very close 
to the C-terminus of the protein (Parkin et al., 2004). In fact it was subsequently 
shown that ADAM10 is the key protease involved in this event and that it cleaves the 
protein between Gly228 and Arg229, which are located only 3 amino acids away from 








1.7. The effects of cell stress-inducing agents on APP 
 processing. 
1.7.1. Hydrogen peroxide and oxidative stress. 
 Hydrogen peroxide (H2O2) is a known to cause oxidative stress (OS) and has 
been associated with Alzheimer’s disease through a disruption in the levels of redox-
active transition metals such as Iron (Fe2+) (Smith et al., 2000). The oxidation of 
aqueous iron to aqueous ferrous iron produces the free radical O2
-, which further 
reacts with hydrogen to produce H2O2 in the equation 2O2
- + 2H+        H2O2 + O2. The 
H2O2 then oxidates ferrous iron to produce OH
- and a more reactive free radical, OH 
(Lauffer, 1992).  
 Several studies have reported that secretases involved in APP processing are 
affected by OS. A positive correlation between elevated levels of oxidative agents 
and the expression and activity of the -secretase, BACE1 was found (Tong et al., 
2004; Kao et al., 2003), promoting the amyloidogenic pathway. To further the 
production of A, in 2008, Tamango et al. found that increased oxidative agents also 
augmented the activity of -secretase by over-expressing PS1 (Tamagno et al., 2008). 
Figure 1.4. The helical to sheet conformational change induced by PrPSc in PrPc and the 
subsequent accumulation/aggregation of PrPSc (Vce.bioninja.com.au, 2017). 
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In addition, a recent study also discovered that ADAM-10 expression was actually 
significantly reduced when exposed to OS from the ozone (Hernández-Zimbrón and 
Rivas-Arancibia, 2015), further hindering the non-amyloidogenic pathwayand 
favouring the production of A.  
Furthermore, studies have indicated that there are also numerous feedback loops 
relating to OS, to enhance and continue the upregulation of the amyloidogenic 
pathway. Firstly, BACE-1 expression was found to be regulated by the activity of the 
-secretase (Guglielmotto et al., 2010), which coincidentally is also increased by OS. 
Research has also shown that the production of A also influences the production of 
additional ROS and oxidative agents. The A residue Tyr10 was found to play an 
essential role in the reduction of Cu2+ to further produce H2O2 (Barnham et al., 2004); 
initiating the cycle again.  
 
1.7.2. Cobalt chloride and hypoxia. 
 Hypoxia occurs when there are reduced levels of oxygen available to cells 
and, as the brain accounts for approximately 20% of the oxygen requirements in the 
human body, neurons are particularly susceptible to hypoxia-induced damage (Sun et 
al., 2006). The cellular response to changing oxygen levels is linked to levels of 
hypoxia inducible factor-1 (HIF-1) that is quickly degraded under normoxic 
conditions (Sun et al., 2006). Cobalt Chloride (CoCl2) is commonly used in research 
experiments as a hypoxia-inducing stressor (Wartenberg et al., 2003), as it blocks the 
degradation of HIF-1 and, consequently, invokes a hypoxic response in cells (Fukuda 
et al., 2002). 
 A history of stroke is a risk factor for the development of AD and can 
approximately double the chance of developing the disease (Sun et al., 2006). This is 
thought to be because stroke and other vascular risk factors cause a lack of blood 
flow to organs or tissues (known as hypoperfusion) leading to hypoxia. In turn, 
hypoxia upregulates the production and aggregation of A-peptides as well as 
impairing memory and causing the destruction of neurons (Daulatzai, 2013). One 
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possible mechanism for the enhanced production of A-peptides lies in the fact that 
the exposure of APPSWE695 SH-SY5Y cells to hypoxia has been shown to increase the 
activity and expression of BACE1 leading to enhanced production of C99 and, 
subsequently, A-peptides (Sun et al., 2006). Furthermore, hypoxia has also been 
shown to reduce the expression of neprilysin (NEP) and endothelin converting 
enzyme-1 (ECE-1), both of which are responsible for the breakdown of A-peptides 
(Nalivaeva & Turner, 2013). Additional studies have found that hypoxia also 
downregulates -secretase activity (Nalivaevaa et al., 2004). Webster et al. (2002) 
showed that hypoxia reduced sAPP production in SH-SY5Y cells by approximately 
60% and that levels of ADAM10 expression were concomitantly reduced by 50%. 
 
1.7.3. Methylglyoxal, thapsigargin and endoplasmic reticulum stress. 
 Methylglyoxal (MG) and thapsigargin (TG) have been used in numerous 
research experiments as inducers of endoplasmic reticulum (ER) stress (Bronner et 
al., 2015, Palsamy et al., 2014). MG is a reactive aldehyde that accumulates in the 
body as a result of hyperglycaemia and is believed to cause ER stress by 
phosphorylating PERK, a protein located in the ER membrane that is involved in the 
unfolded protein response (UPR) (Palsamy et al., 2014). MG can also increase ROS 
levels, enhance the production of advanced glycation end products (AGEs) (Angeloni 
et al., 2014) and induce the release of ER calcium stores into the cytosol (Palsamy et 
al., 2014). Thapsigargin originates from the plant Thapsia garganica and is believed 
to induce ER stress by inhibition of the sarcoplasmic or endoplasmic reticulum Ca-
ATPase (SERCA) calcium pumps (Lytton et al., 1991). These pumps usually regulate 
calcium homeostasis and their inhibition results in a release of ER calcium into the 
cytoplasm. 
 It has recently been suggested that ER stress could be linked to neuronal 
death and AD with elevated calcium levels being found in the neurons of AD patients 
(Murray et al., 1992). A mutation in the PS1 gene present in a number of FAD cases 
has been shown to downregulate the UPR and consequently increases ER stress that 
can result in apoptosis and neuronal death (Katayama et al., 2014). Additionally a 
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variant of the PS2 gene (PS2V), created by alternate splicing, has also been linked to 
ER stress (Chadwick et al., 2012). The authors found that cells expressing PS2V 
demonstrated a vulnerability to ER stress similar to that of cells expressing FAD PS1 
mutants. This was thought to be due to PS2V hindering the UPR by inhibiting 
phosphorylation of the ER stress transducer, IRE1.  
 A number of studies have also indicated that ER stress can have an impact on 
the transport and processing of APP. PS2V has been shown to inhibit the transit of 
APP from the ER to the Golgi thereby impairing maturation of the protein (Chadwick 
et al., 2012). In addition, APP expression is elevated by AGEs (Angeloni et al., 2014) 
and APP proteolysis is altered by disruptions in cellular calcium homeostasis, which 
itself can be affected by presenilins (Chadwick et al., 2012; Jung et al., 2015). 
Furthermore, the expression of BACE-1 is also increased by ER stress (Salminen et al., 
2009). It was also found that the A-peptide aggregation can be enhanced by MG 
and that A-peptides glycated by AGEs are more toxic than normal A(Angeloni et 
al., 2014).  
 In healthy brain tissue, sAPP exhibits neurotrophic properties in response to 
ER stress and elevated sAPP is protective against TG-induced apoptosis (Endres & 
Reinhardt, 2013). However, when cytosolic calcium is increased, -secretase activity 
is impaired and sAPP generation is concomitantly reduced (Chadwick et al., 2012). 
It is also notable that the expression of seladin-1/DHCR24, an ER enzyme that 
modulates APP processing and also exhibits neuroprotective properties especially 
against the neurotoxicity produced by A, is decreased in AD (Salminen et al., 2009).  
 
1.8. Glucagon-like peptide-1 analogues. 
 Glucagon-like peptide-1 receptor (GLP-1R) agonists (or GLP-1 analogues) are 
currently used as a treatment for type 2 diabetes mellitus. Their function is to mimic 
the incretin hormones found naturally in the body, which are normally responsible 
for regulating blood sugar. They work by increasing the release of insulin, inhibiting 
the release of glucagon and reducing the speed at which the stomach contents are 
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emptied; which consequently slows the process of glucose absorption 
(Diabetes.co.uk, 2017). There are four types of GLP-1 agonists currently administered 
to diabetic patients with the generic names Lixisenatide, Dulaglutide, Liraglutide, and 
Exenatide (Exendin-4). The current study focuses on Liraglutide and Exendin-4.  
 Exendin-4 is a naturally occurring 34 amino acid homologue of human GLP-1 
and is found in the saliva of the Gila monster, Heloderma suspectum (Donnelly, 
2012). It boasts many similarities to GLP-1 but, with a homology of only 53%, it also 
exhibits many differences. The second N-terminal amino acid of GLP-1, alanine, is 
replaced by glycine in Exendin-4. As this alanine residue harbours the site for 
proteolytic inactivation of GLP-1 by dipeptidyl-peptidase-4 (DPP-4), Exendin-4 is 
resistant to this cleavage (Gupta, 2013).  
 Liraglutide is a synthetic analogue of human GLP-1 (Donnelly, 2012). It bears 
97% sequence homology to human GLP-1 as it only has a single lysine to arginine 
substitution at residue 34. The only other variation is that of a C-16 acyl group 
addition to lysine26 in Liraglutide, which increases the binding of albumin thereby 
protecting the molecule from DPP-4 cleavage and inactivation. The acylation also 
downregulates renal clearance and therefore, the excretion of Liraglutide (Gupta, 
2013). Collectively, these changes extend the half-life of GLP-1 from approximately 2 
min to 13 h in the case of Liraglutide (Agersø et al., 2002). 
 There are some links between type 2 diabetes and AD and the former is 
certainly a risk factor for the latter (Peila, Rodriguez and Launer, 2002). In addition, 
insulin may also have neuroprotective properties (Tanaka et al., 1995) and has roles 
in neurogenesis and proliferation, as well as in elevating activity at synapses and 
enhancing the formation and storage of memories (Kremerskothen et al., 2002). It 
has also been reported that insulin affects -secretase activity and upregulates the 
transportation of A to the plasma membrane (Gasparini et al., 2001) reducing the 
levels in the ER and, therefore, possibly preventing ER stress.  
 In diabetes the function of insulin is impaired either due to decreased levels 
or signaling dysfunction, which result in hyperinsulinemia. This is believed to 
inactivate the insulin receptors located in the blood brain barrier (BBB), which 
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consequently reduces the amount of insulin reaching the brain, causing a number of 
defects in brain activity and cognitive abilities (Schwartz et al., 1990). One study 
reported that, when compared with type 1 diabetes mellitus (which results from 
depleted levels of insulin), the neuronal degeneration and defective proteolysis of 
APP were more apparent in cases of type 2 diabetes mellitus (Li et al., 2007). This 
indicates that the neurodegenerative effects associated with diabetes are most likely 
a result of insulin resistance and the subsequent deficit of insulin, rather than 
inadequate levels of insulin alone. Furthermore, hyperinsulinemia has also been 
associated with elevated A-peptideaccumulation as the probable result of direct 
substrate competition between insulin and A-peptides for the insulin degrading 
enzyme (IDE) (Qiu & Folstein, 2006). Hyperinsulinemia is also associated with the 
generation of ROS and AGEs that may contribute to the development of AD (Vincent 
et al., 2005). 
 Recently, it has been reported that GLP-1 agonists might possess therapeutic 
properties against neurodegeneration and, therefore, could be a potential target for 
the treatment of neurodegenerative diseases (Shimoda et al., 2011, Chen et al., 
2012). They have been reported to enhance cognitive abilities and improve LTP, as 
well as increasing synaptic plasticity (Hölscher, 2010). Furthermore, they are able to 
traverse the BBB and display neurotrophic and neuroprotective properties in the 
central nervous system (CNS) (Kastin & Akerstrom, 2003). GLP-1 agonists have also 
been reported to exhibit neuroprotective abilities in retaliation to hypoxia and 
oxidative stress, both of which are involved in AD, and to protect the brain against 
damage in a number of neurological conditions such as stroke and Parkinson’s 
disease (Li et al., 2009). 
 Liraglutide, specifically, has been shown to elevate synaptic plasticity, 
improve cognitive function and memory formation, and to reduce the formation of 
A plaques in an APP/PS1 transgenic mouse model of AD (McClean et al., 2011). 
 Exendin-4, specifically, exerts neuroprotective properties against oxidative 
stress (Chen et al., 2012) and glutamate excitotoxicity (Perry et al., 2002) and 
reduces A-peptidelevels in neurons in vitro and in female mice treated with 
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streptozotocin (Li et al., 2010). It was recently reported that Exendin-4 increased 
membrane protein levels of the postsynaptic density protein-95 (PSD-95) and the 
AMPA receptor GluR1, as well as expression levels of brain-derived neurotrophic 
factor (BDNF) in the mouse neocortex, all of which play a role in the generation and 
plasticity of synapses (Ohtake et al., 2014). The same report showed that Exendin-4 
also enhanced levels of ADAM10 in the cell membrane fraction suggesting that the 
GLP-1 agonist promotes trafficking of the enzyme to the plasma membrane. 
 
1.9. Summary.  
 It is clear from the literature that GLP-1 agonists, including Exendin-4 and 
Liraglutide, exhibit neuroprotective effects. Their ability to combat oxidative damage 
and neurodegeneration, as well as their existing clinical use in the treatment of 
diabetes, makes them ideal candidates for repurposing for the treatment of 
neurodegenerative diseases, especially Alzheimer’s disease. The recent observation 
that Exendin-4 promotes the trafficking of ADAM10 could also represent a 
mechanism by which the drugs reduce A-peptide production i.e. by enhancing the 
reciprocal non-amyloidogenic pathway of APP proteolysis. ADAM10 also has many 
other substrates and its activation is, therefore, potentially relevant to other 
conditions such as the TSEs and schizophrenia.  
 The aim of the current investigation is to characterise the protective effects 
of the GLP-1 agonists, Exendin-4 and Liraglutide, against various chemical stressors 
used to treat the neuroblastoma cell line, SH-SY5Y. Furthermore, the effect of GLP-1 
agonists on the ADAM10-mediated proteolysis of APP, PrP and NLGN-1 will be 
examined in the same cell line and correlated with any protective effects of the 
drugs. Studies of this type should aid our understanding of the protective 



























2.1.  Materials. 
 The generation of the human APP695 construct in the mammalian expression 
vector pIREShyg (Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) and 
the human prion construct in the mammalian expression vector pIRESneo (Clontech-
Takara Bio Europe, Saint-Garmain-en-Laye, France) has been published previously 
(Parkin et al., 2007). Details of the human ADAM10 construct in pIRESneo have also 
been published (Parkin & Harris, 2009). The human neuroligin-1 construct in 
pIRESneo was synthesized and sequenced by Epoch Biolabs (Missouri City, USA). 
 
 The anti--actin monoclonal antibody and the anti-APP-CT polyclonal 
antibody were from Sigma-Aldrich Co. (Poole, UK). The SAF 32 (anti-prion) 
monoclonal antibody was purchased from SPI bio/ Bertin Pharma (Montigny le 
Bretonneux, France). The anti-ADAM10 C-terminal polyclonal antibody was 
purchased from Merck/Millipore (Temecula, USA). The neuroligin-1 (cytoplasmic 
domain) polyclonal antibody and neuroligin-1 (extracellular domain) polyclonal 
antibody were purchased from Synaptic Systems (Göttingen, Germany). The anti-
sAPP (6E10) monoclonal antibody and the anti-sAPP polyclonal antibody were 
purchased from Biolegend (San Diego, USA). The goat anti-rabbit secondary antibody 
and the rabbit anti-mouse secondary antibody were purchased from Sigma-Aldrich 
Co. (Poole, UK). 
 Unless otherwise stated, cell culture reagents were purchased from Scientific 
Laboratory Supplies (Nottingham, UK) and all other reagents were purchased from 
Sigma-Aldrich Co. (Poole, UK). 
 
2.2.  Methods. 
2.2.1.  Cell culture. 
 Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% (v/v) Foetal Calf Serum (FCS) and a 
penicillin/streptomycin mixture (10 units/ml penicillin, 10 µg/ml streptomycin). 
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Cultures were grown at 37°C in a 5% (v/v) CO2 environment and the medium was 
replaced every 2-3 days.  
 For splitting, 2 ml of trypsin was added to the flask and removed to eliminate 
any residual media, before being replaced with a fresh 2 ml of trypsin and incubated 
for approximately 5 min. The flask was then tapped gently and viewed under a 
microscope, to ensure all cells had detached from the bottom of the flask. 20 ml of 
growth medium was added to the flask containing the trypsinized cells and the 
trypsin/medium mixture was transferred to a 50 ml Falcon tube. The cells were 
centrifuged at 800 rpm for 5 min in an Allegra X-22R centrifuge (Beckman Coulter, 
California, USA) for 3 min before removing the residual medium to leave an 
undisturbed pellet. The pellets were resuspended in 10 ml of growth medium and 1 
ml of resuspension was added to each new flask, containing 10 ml of fresh growth 
medium.   
 
2.2.2.  Treatment of cells with drugs and stressors. 
 A confluent T75 flask of SH-SY5Y cells was trypsinized and cells were pelleted 
as described in section 2.2.1. and the cells were resuspended in 30 ml of complete 
growth medium. Growth medium (150 l) and resuspended cells (50 l) were added 
to the required number of wells in a 96-well microtitre plate. Cells were then 
cultured until they reached 80-90% confluency at which point the growth medium 
was removed and the cells were washed in situ with 200 µl of UltraMEM followed by 
the addition of a fresh 200 µl of the same medium to each well of cells. Stressors and 
drugs were incorporated into this latter volume of UltraMEM. 
 Thapsigargin (TG) stock was made by dissolving the supplied 5 mg of 
lyophilized powder in 961.5 l of dimethyl sulfoxide (DMSO). Adding 2.5 l of this 
stock per 200 l of medium then gave a final concentration of 100 M. All other 
dilutions of TG were made by diluting this solution with DMSO such that the same 
volume of solution (2.5 l per 200 l medium) could be added to achieve the desired 
final concentrations. DMSO was incorporated into control cultures.  
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Methylglyoxal (MG) was supplied as a 40% (w/v) stock solution which was diluted 1 : 
99 (MG : distilled water) to give a final working solution which was then filter-
sterilized under aseptic conditions. Adding 4.3 l of this working solution to 200 l of 
growth medium then gave a final MG concentration of 1200 M. All other MG 
concentrations were made by diluting the initial solution with filter-sterilized water.  
In the case of hydrogen peroxide, a 30% (w/v) stock solution was diluted 1:199 in 
distilled water. After filter-sterilizing, the addition of 2.3 l of this dilution to 200 l 
of culture medium gave a final concentration H2O2 of 1000 M. All other 
concentrations were achieved by diluting the 1:199 solution with filter-sterilised 
distilled water.  
For cobalt chloride (CoCl2) treatments 0.1 g was dissolved in 10 ml distilled water and 
filter-sterilised. The addition of 5 l of this stock to 200 l of culture medium gave a 
final CoCl2 concentration of 1000 M. All other concentrations were achieved by 
diluting the stock with filter-sterilized water.  
 Liraglutide (LG) and Exendin-4 (E-4) were utilised as follows. A LG stock was 
made up at an 83 mM concentration using distilled water, aliquoted and frozen at -
25 oC. This stock was then diluted 1:1999 with distilled water and filter-sterilized such 
that adding 3 l of this solution to 200 l of growth medium gave a final LG 
concentration of 500 nM. All other final concentrations were achieved by diluting the 
1:1999 solution with filter-sterilized distilled water. E-4 (1 mg) was dissolved in 29.85 
ml of distilled water, aliquoted and frozen at -80oC. This stock was then diluted 1:40 
in growth medium and this solution was applied directly to cells (after filter-
sterilizing) to give a final E-4 concentration of 200 nM. Further dilutions were made 
by adding filter-sterilized growth medium to the 1:40 solution. Note that medium on 
control cells was also filter-sterilized. Batimastat was made up as a 10 mM stock in 
DMSO and 10 l of this stock was added to every 10 ml of medium to give a final 





2.2.3. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
 sulfophenyl)- 2H-tetrazolium) cell proliferation assay. 
 After stressor and/or drug treatments, 20 µl of CellTiter 96 Aqueous One 
Solution (Promega Corporation, Madison, USA) was added to each 200 l of medium 
in the wells of the 96-well microtitre plate containing the treated cells (along with 
blank wells containing just medium) and the plate was mixed thoroughly by 
extensive tapping on the edge of the bench. The plate was then covered in tin foil 
and incubated at 37C until the brown colouration had developed sufficiently (10 min 
-1 h). During this incubation the plate was intermittently tapped on the bench to 
dissolve the precipitate effectively. The absorbance of the samples was then read at 
490 nm using a wallac VICTOR2 spectrophotometer. Blank values were then 
subtracted from the sample readings. 
 
2.2.4.  Conditioning medium for analysis of protein shedding. 
 Once at the appropriate confluence the spent growth medium was removed 
from cells in T75 flasks and replaced with 10 ml of UltraMEM reduced serum 
medium. Flasks were gently rocked by hand and the UltraMEM was removed before 
adding a fresh 10 ml of the same medium and culturing the cells for a further 24 h. 
The medium was then collected and stored at -80oC pending concentration. 
 
2.2.5.  Concentrating conditioned medium samples. 
 The medium was thawed in a 37°C water bath and then kept on ice. 
Centrifugal concentrators (Amicon Ultra-4, Merck Millipore Ltd., Cork, Ireland) were 
first equilibrated by adding 4 ml distilled water and centrifuging at 4000 rpm in a 
Hettich Rotanta 460R centrifuge (Hettich, Tuttlingen, Germany) until the water had 
spun through (approximately 10 min). The water was then removed from the base of 
the concentrator. Cell debris was pelleted from the conditioned medium samples by 
centrifuging at 4000 rpm for 5 min. A total of exactly 8 ml of supernatant from each 
sample was then concentrated to 250 l by spinning for the required amount of time 
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in the concentrators at 3000 rpm. Concentrated samples were then removed into 
Eppendorf tubes and stored at -80oC pending further analysis. 
 
2.2.6.  Harvesting cells. 
 Following the removal of conditioned medium from cell cultures (see section 
2.2.4.), 10 ml of phosphate-buffered saline (PBS; 1.5 M NaCl, 20 mM NaH2PO4 and 
200 mM Na2HPO4, pH 7.4) was added to each flask and was gently swilled around for 
approximately 1 min. The PBS was decanted off and a fresh 10 ml of the same buffer 
was added, into which the cells were scraped.  The cell suspension was then 
transferred into a 50 ml Falcon tube and a fresh 10 ml of PBS was added to the flask 
to rinse out the remaining cells; this was then combined with the first 10 ml in the 
same Falcon tube. The tubes were then centrifuged at 500 rpm in a Hettich Rotanta 
460R centrifuge (Hettich, Tuttlingen, Germany) for 5 min (4oC) to pellet the cells. The 
supernatant was decanted and any remaining PBS was removed using a Gilson 
pipette.  
 
2.2.7.  Preparation of cell lysates. 
 Cell pellets were resuspended in 1.5 ml of lysis buffer (50 mM Tris, 150 mM 
NaCl, 1% (v/v) Igepal, 0.1% (w/v) Sodium Deoxycholate, 5 mM EDTA 
(Ethylenediaminetetraacetic acid), pH 7.4) which had previously had a protease 
inhibitor cocktail (Sigma-Aldrich Co., Poole, UK) added to it at a volume ratio of 100:1 
(lysis buffer:cocktail). The cells were then resuspended by pipetting up and down five 
times. Next, the samples were sonicated using a probe sonicator on half power for 
30 s (MSE, Crawley, UK) and then transferred to 1.5 ml Eppendorf tubes before 
centrifuging at top speed for 10 min in a bench top microfuge. The supernatants 
(lysates) were then removed into fresh tubes and, after equalizing protein 




2.2.8.  Bicinchoninic Acid (BCA) Assay. 
 In order to quantify the amounts of protein in lysate samples, a BCA protein 
assay was performed using bovine Serum Albumin (BSA) to generate a standard 
curve/line. Standards (10 l) were added, in duplicate, to the wells in the first row of 
a 96-well microtitre plate in the order described below: 
 
A1+A2:  0.2 mg ml-1 BSA 
A3+A4:  0.4 mg ml-1 BSA 
A5+A6: 0.6 mg ml-1 BSA 
A7+A8:  0.8 mg ml-1 BSA 
A9+A10: 1.0 mg ml-1 BSA 
A11+A12: 0 mg ml-1 BSA (distilled water) 
 
 Lysate samples (10 l) were then added in duplicate starting in the second 
row of the plate. A working reagent of 50:1 (v/v) BCA : 4% (w/v) CuSO4.5H2O (BCA; 
Pierce, Rockford, USA) was then prepared and 200 l was added to each well of the 
plate (samples and standards). Samples were thoroughly mixed by gentle tapping of 
the plate on the edge of the bench and any air bubbles were removed using a 
hypodermic needle before incubating the plate for 30 min at 37°C. The absorbance of 
samples was measured at 562 nm using a Wallac VICTOR2 spectrophotometer (Perkin 
Elmer, Waltham, USA). A standard regression line was generated using the BSA 
readings and sample protein concentrations determined using the resultant 
regression equation. All lysate samples were then equalized to the protein 
concentration of the lowest sample by adding the required volume of lysis buffer 
calculated using the equation below: 
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Volume to be added = ((concentration of most concentrated sample/ concentration 
of most dilute sample) x volume of most concentrated sample) – volume of most 
concentrated sample. 
 
2.2.9.  Sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
 SDS-PAGE was carried out using 7-20% gradient resolving gels (Table 2.1). 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) (3µl) was added to both the 7% and 
the 20% solutions before gently inverting to mix. The resolving gels were then 
poured using a gradient mixer and peristaltic pump and layered with isopropanol in 
order to exclude oxygen that might otherwise inhibit polymerization. After 
approximately 30 min the isopropanol was completely removed and the stacking gel 
(Table 2.2) was poured (after the addition of 15µl of TEMED to the solution) before 
inserting the well comb. After allowing the stacking gel to set (30 min), the comb was 
removed and the gels were transferred to the running kit and the electrode 
reservoirs were filled with running buffer (0.25 M Tris, 1.92 M Glycine and 1% SDS; 
Geneflow Ltd, Lichfield, UK). 
 Samples were diluted 2:1 (v:v) with dissociation buffer (3.5 ml 1 M Tris/HCl, 
pH 6.8, 2.5 g SDS, 0.3085 g dithiothreitol, 5 ml glycerol, 0.05 mg bromophenol blue, 
made up to 25 ml with distilled water) and gently vortexed. A low molecular weight 
standard marker ladder (GE Healthcare, Buckinghamshire, UK)) was prepared in the 
same manner by diluting with dissociation buffer as were blank solutions containing 
just distilled water and dissociation buffer. All samples, standards and blanks were 
then boiled for 3 min and 30 µl aliquots were loaded in the gel wells. Gels were run 







Table 2.1. Resolving gel composition. 
 % Acrylamide 
Component 7% 20% 
Sucrose - 0.37 g 
1 M Tris/HCl pH 8.8 1.39 ml - 
1.5 M Tris/HCl pH 8.8 - 0.93 ml 
30% acrylamide  
0.8% Bis (Universal 





1.5% (w/v) ammonium 
persulfate 
0.1 ml 0.22 ml 
Distilled water 1.36 ml - 
10% (w/v) SDS 37 µl 37 µl 
 
Table 2.2. Stacking gel composition. 
Component Volume 
1 M Tris/HCl pH 6.8 1.89 ml 
30% acrylamide  
0.8% Bis (Universal Biologicals, 
Cambridge, UK) 
1.5 ml 
1.5% (w/v) ammonium sulphate 0.75 ml 
Distilled water 11.49 ml 








2.2.10.  Immunoblotting. 
 Polyvinylidene difluoride (PVDF) transfer membranes (Millipore, Billerica, 
USA) were activated by placing them in methanol for 5 s, distilled water for 2 min 
and Towbin transfer buffer (20 mM Tris and 150 mM glycine in 20% (v/v) methanol) 
for at least 10 min. The SDS-PAGE gels were also equilibrated in Towbin buffer for 
approximately 5 min. Transfer sandwiches were assembled consisting of; 3 x blotting 
paper, 1 x membrane, 1 x gel, 3 x blotting paper. All blotting paper was soaked in 
Towbin buffer and layers were rolled with a test-tube to eliminate air bubbles. The 
sandwiches were placed in the wet blot transfer kit which was filled with Tobin 
buffer and the lid was attached such that the positive electrode was on the 
membrane side of the sandwich. Proteins were transferred at 115V for 1 h. Following 
transfer, the PVDF membranes were washed in PBS for 5 min before blocking them 
for 1 h at room temperature in 5% (w/v) skimmed milk powder in PBS + 0.1% (v/v) 
Tween-20 (PBS-Tween) on a rotating platform. The blocking buffer was then 
removed and the membranes were washed in PBS for a further 5 min. Primary 
antibodies were then added to the membranes which were incubated either on a 
shaking platform or a spiramix overnight at 4oC. All primary antibodies (Table 2.3) 
were made up in PBS-Tween containing 2% (w/v) BSA. The next morning, the primary 
antibody solution was removed and the membranes were washed for 1 x 1 min and 2 
x 15 min in PBS-Tween. Secondary antibody (made up in the same solution as the 
primary antibody) (Table 2.3) was then incubated with the membranes for 1 h at 
room temperature on a rotating platform. The membranes were then washed for a 









Table 2.3. Primary and secondary antibodies used for immunoblotting. 












































































2.2.11. Immunoblot Development. 
 The PBS from the final membrane wash was discarded and Enhanced 
Chemiluminescence (ECL) reagent (Pierce, Rockford, USA).  6 ml was incubated on 
the membrane for 2 min with thorough manual mixing. The membrane was then 
placed between two sheets of acetate in a developing cassette and a sheet of X-ray 
film was placed on top before closing the cassette. Exposures were performed for 
between 2 min and 1 h before developing and fixing the films. 
 
2.2.12. Amido black staining. 
 The membranes were removed from the acetate sheets and placed in Amido 
Black solution (0.1% (w/v) amido black, 1% (v/v) acetic acid, 40% (v/v) methanol) for 
approximately 1 minute, until the bands appeared. They were then rinsed under cold 
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water until the excess Amido Black was removed from the background and the bands 
were clearly prominent.  
 
2.2.13. Bacterial DNA transformation. 
 XL1-blue E.Coli (20 l) (Agilent Technologies LDA UK Ltd, Stockport, UK) were 
aliquoted into Eppendorf tubes and placed on ice. Following the addition of 0.3 l of 
-mercaptoethanol (1.42 M), the bacteria were incubated on ice for 10 min with 
gentle swirling every 2 min. Stock DNA (1 l) was then added to each aliquot of 
bacteria before incubating on ice for a further 30 min. The cells were then heat 
shocked at 42 oC for exactly 45 secs before being returned to ice for a further 2 min. 
LB (0.9 ml; 10g Bacto-tryptone, 5 g Bacto-yeast extract, 5 g NaCl, 1 L d.H2O, pH 7.5) 
prewarmed to 37oC was then added to each transformation and the samples were 
incubated on a shaker for 1 h at 37oC. The bacteria were then pelleted by 
centrifugation at 2000 rpm for 10 min in a bench top microfuge and 800 l of the 
supernatant was removed. The remaining liquid in the tube was then used to 
resuspend the bacteria and they were plated on agar-ampicillin plates. Plates were 
made by adding 7.5 g agar to 500 ml LB, autoclaving and cooling to 45 oC for 1 h prior 
to the addition of 500 l of 100 mg/ml filter-sterilized ampicillin and subsequent 
pooring. The plates were incubated at 37 oC overnight and then a single colony was 
selected from the plate and inoculated into 5 ml of LB/penicillin. These mini-
suspension cultures were grown overnight at 37 oC with shaking before inoculating 
0.5 ml of the culture into a 50 ml midi-suspension culture and growing again 
overnight. 
 
2.2.14.  DNA purification. 
 The bacterial cells from the suspension cultures (section 2.2.13) were 
harvested by centrifuging at 6000 g for 15 min at 4°C. The DNA was then prepared 
using the QIAGEN Plasmid Midi Kit according to the manufacturer's instructions. The 
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final DNA pellet was air-dried for 5-10 min and resuspended in 200 l of distilled 
water followed by heating to 60 oC for 10 min and repeated pipetting. 
 
2.2.15. Restriction enzyme digests. 
 Purified plasmid DNA was linearized by restriction digest prior to stable 
transfections being performed. Digest incubations consisted of the following 
components: 
 
5 µl of 10x restriction enzyme buffer (NEB buffer 4 for Ahd1, and CutSmart Buffer for 
Xho1) 
0.5 µl acetylated BSA (10 g/ l stock?) 
0.5 l  Ahd1 or Xho1 (the latter for the Neuroligin1 plasmid) restriction enzyme 
15-30 g of plasmid DNA 
RNAase-free distilled water to make up to 50 l 
 
Digests were then incubated overnight at 37°C 
 
2.2.16. Ethanol precipitation of digested plasmids. 
 Filter-sterilised sodium acetate (3M, p.H 5.2) (1/10 volume) was added to the 
restriction digests along with cold absolute ethanol (2 volumes) before mixing and 
incubating the solutions at -20°C for 1 h. The samples were then centrifuged at 
11,600 g for 20 min at 4°C and the supernatant was removed. Cold 80% (v/v) ethanol 
(300 µl) was added to the pellet without resuspension followed by centrifugation as 
before but for just for 5 min. The supernatant was discarded and the pellet was 
resuspended, under aseptic conditions, in 30 l of filter-sterilized distilled water. 
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2.2.17.  Stable transfection of mammalian cells. 
 A T75 flask of 70% confluent SH-SY5Y cells was trypsinized and pelleted as 
described in section 2.2.1. The cell pellet was resuspended in 0.8 ml of growth 
medium before being transferred to an electroporation cuvette (Bio-rad, 0.4cm Gene 
Pulser/Micropulser). The plasmid resuspension (20 l) was added to the cuvette and 
the sample was mixed by repeated pipetting. The cuvette was then electroporated 
using an ECM630 electroporator (Bio-rad, square wave, 120 V, 25 ms, 2 mm path 
width). The cells were resuspended in 5 ml of growth medium and transferred to a 
T75 flask containing 20 ml growth medium. The next morning, the growth medium 
was changed for a fresh 20 ml and the cells were grown to approximately 60% 
confluence, with the medium being changed every other day. At this point, the cells 
were treated with antibiotic (50 µl per 10 ml of medium of 0.1 g ml-1 neomycin stock 
or 30µl per 10 ml medium of 50 mg ml-1 Hygromycin stock) until the selection control 
cells (i.e. no plasmid transfections) had completely died off.  
 
2.2.18.  Statistical analysis. 
 Results are expressed as means +/- S.D. or S.E.M. (as indicated in Figure 
legends) with the number of repeats indicated in the relevant Figure legends. 
Significance was tested using Student's t-test and the level of significance is indicated 































3.1. The effects of GLP-1 analogues on SH-SY5Y cell viability   
        under stress conditions. 
 GLP-1 analogues have previously been shown to protect cells against various 
stressors (Li et al., 2009, Chen et al., 2012). Therefore, in the current study, the 
ability of liraglutide and exendin-4 to protect SH-SY5Y neuronal cells against various 
chemical stressors was initially examined. 
3.1.1. Determination of cell seeding levels. 
In order to achieve a suitable level of confluence within a reasonable time 
frame it was first necessary to determine the appropriate number of cells to seed 
into 96 well plates. Unfortunately, SH-SY5Y cells remain in uncountable clumps even 
after careful trypsinisation. Therefore, cells were allowed to reach confluency in a 
T75 flask, trypsinised and then resuspended in 10 ml of growth medium. A range of 
volumes of this resuspension were then added to the wells of 96 well plates together 
with sufficient growth medium to bring the volumes in all wells to 200 l. The cells 
were then cultured until the first wells reached confluency (48 h) and then an MTS 
assay (see Materials and Methods) was performed in order to determine cell 
viability. The results (Fig. 3.1.1.) show that, when 100 l of the cell resuspension was 
added to each well, confluency was achieved within the 48 h time frame. The 
remaining volumes of resuspension gave variable levels of confluence within the 
same time frame. These data enabled the seeding of appropriate volumes of cell 
resuspensions to achieve the required level of cell confluence in subsequent 
experiments (experimental plates were always seeded from the cell pellet of a 
trypsinised confluent T75 flask of cells resuspended every time in the same volume 

























Volume of cell resuspension seeded (μl) 
Figure 3.1.1. Determination of SH-SY5Y cell seeding volumes. A confluent T75 flask of cells was 
trypsinised, pelleted and resuspended in 10 ml of complete growth medium before seeding out 100, 
50, 10, 2, and 1 l of resuspension into the wells of a 96 well plate. All wells in the plate were made 
up to 200 l by the addition of further growth medium and the cells were cultured for 48 h. Once the 
first wells reached confluence an MTS assay was performed as described in the Materials and 
Methods section. Results are expressed as a percentage of the completely confluent (100 l cell 










3.1.2. GLP-1 analogues and hydrogen peroxide treatment 
Hydrogen peroxide was used as an initial stressor as an oxidative stress 
causative agent. It has previously been reported that hydrogen peroxide induces the 
production of reactive oxygen species (ROS) (Smith et al., 2000). Initially, hydrogen 
peroxide toxicity curves were generated. SH-SY5Y cells were seeded into 96 well 
plates, grown to 80% confluence and then washed in situ with complete growth 
medium. Fresh growth medium containing a range of hydrogen peroxide 
concentrations was then added to the cells and they were then cultured for a further 
24 h before conducting an MTS cell viability assay as described in the Materials and 
Methods section. The results (Fig. 3.1.2.) show that only the 1000 μM concentration 
of hydrogen peroxide was cytotoxic when the stressor was added to cells in complete 
growth medium. It was subsequently hypothesized that components in the complete 
growth medium might be impacting on the toxicity of the hydrogen peroxide so the 
experiment was repeated but this time the stressor was added to cells in UltraMEM 
as opposed to complete growth medium. The results (Fig. 3.1.3.) show that, under 
these conditions, the stressor was cytotoxic at both 500 μM and 1000 μM 
 39 
 
Figure 3.1.2. The effect of hydrogen peroxide on SH-SY5Y cell viability in the presence of complete 
growth medium. Cells were grown to 80% confluence, washed in situ with complete growth medium 
and then 0, 50, 100, 200, 500,  and 1000  Mhydrogen peroxide in complete growth medium was 
added to the cells. Following a further 24 h culture period, an MTS cell viability was performed as 
described in the Materials and Methods section. Results are expressed as a percentage of the control 































concentrations. Subsequently, the cytotoxicity of additional hydrogen peroxide 
concentrations between 200 and 500 M was also examined. Both 300 and 400 M 
stressor concentrations resulted in similar toxicity (Fig. 3.1.4.). For future 
experiments testing the protective effects of GLP-1 analogues it was decided to 





































































Figure 3.1.3. The effect of hydrogen peroxide on SH-SY5Y cell viability in the presence of UltraMEM. 
Cells were grown to 80% confluence, washed in situ with UltraMEM and then 0, 50, 100, 200, 500, 
and 1000 M hydrogen peroxide in UltraMEM was added to the cells. Following a further 24 h culture 
period, an MTS cell viability was performed as described in the Materials and Methods section. 
Results are expressed as a percentage of the control viability and are means ± S.D. (n=3). 
 
Figure 3.1.4. The effect of hydrogen peroxide on SH-SY5Y cell viability in the presence of UltraMEM. 
Cells were grown to 80% confluence, washed in situ with UltraMEM and then 0, 200, 300, 400, and 
500 M hydrogen peroxide in UltraMEM was added to the cells. Following a further 24 h culture 
period, an MTS cell viability was performed as described in the Materials and Methods section. 



















Figure 3.1.5. The effect of liraglutide on the viability of SH-SY5Y cells treated with 500 M hydrogen 
peroxide. Cells were grown to 80% confluence, washed in situ with UltraMEM and then 500 M 
hydrogen peroxide and 75, 150, 300, and 750 nM liraglutide in UltraMEM were added to the cells. 
Following a further 48 h culture period, an MTS cell viability was performed as described in the 
Materials and Methods section. Results are expressed as a percentage of the control viability at each 
liraglutide concentration and are means ± S.D. (n=3) with the exception of 150 nM Liraglutide and 75 

































3.1.2.1. Liraglutide and hydrogen peroxide treatment 
Next, the ability of liraglutide to protect cells against hydrogen peroxide-
mediated toxicity was examined. Cells were once more cultured until they were 80% 
confluent before being washed in situ with UltraMEM and then being treated with 
fresh UltraMEM containing 500 M hydrogen peroxide and/or liraglutide (0, 75, 150, 
300 or 750 nM). Following a 48 h incubation, an MTS cell viability assay was 
performed as described in the Materials and Methods section. The results (Fig. 3.1.5) 
showed that, whilst 500 M hydrogen was highly toxic to the cells, liraglutide 
exerted no protective effect against the stressor. It was hypothesized that the 
hydrogen peroxide concentration used in this experiment may simply have been too 
harsh for the liraglutide to show any protective effect. Consequently, the experiment 
was repeated at lower stressor concentration (300 M). However, the results from 










Figure 3.1.6. The effect of liraglutide on the viability of SH-SY5Y cells treated with 300 M hydrogen 
peroxide. Cells were grown to 80% confluence, washed in situ with UltraMEM and then 300 M 
hydrogen peroxide and 75, 150, 300, and 750 nM liraglutide in UltraMEM were added to the cells. 
Following a further 48 h culture period, an MTS cell viability was performed as described in the 
Materials and Methods section. Results are expressed as a percentage of the control viability at each 










































Given that liraglutide failed to protect against hydrogen peroxide treatment when 
the stressor and GLP-1 were added to cells concurrently, it was decided to test the 
effect of pre-treating cells with liraglutide on the toxicity of hydrogen peroxide. To 
this end, cells were grown to 60% confluency  to account for inevitable further 
growth during pretreatment and a consequent confluency of approximately 80% 
upon treatment. The cells were then pre-treated with liraglutide for 24 h (in 
complete growth medium) before washing them in situ with UltraMEM and 
incubating them for an additional 48 h containing hydrogen peroxide and or fresh 
liraglutide. An MTS viability assay was then performed as described in the Materials 
and Methods section.  Whilst a range of hydrogen peroxide concentrations (200, 300 
and 500 M) were tested, no protective effect of liraglutide was evident against 300 
and 500 M stressor concentrations (Figs. 3.1.7. and 3.1.8.). However, in contrast, 
when the lower 200 M hydrogen peroxide concentration was tested (Fig. 3.1.9.), 




Figure 3.1.7. The effect of liraglutide pre-treatment on the viability of SH-SY5Y cells treated with 
500 M hydrogen peroxide. Cells were grown to 60% confluence and then pre-treated for 24 h with 
75, 150, and 750 nM liraglutide in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 500 M hydrogen peroxide and 75, 150, and 750 nM fresh liraglutide in 
UltraMEM were added to the cells. Following a further 48 h culture period, an MTS cell viability was 
performed as described in the Materials and Methods section. Results are expressed as a percentage 
of the control viability at each liraglutide concentration and are means ± S.D. (n=3). 
Figure 3.1.8. The effect of liraglutide pre-treatment on the viability of SH-SY5Y cells treated with 
300 M hydrogen peroxide. Cells were grown to 60% confluence and then pre-treated for 24 h with 
75, 150, and 750 nM liraglutide in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 300 M hydrogen peroxide and 75, 150, and 750 nM  fresh liraglutide in 
UltraMEM were added to the cells. Following a further 48 h culture period, an MTS cell viability was 
performed as described in the Materials and Methods section. Results are expressed as a percentage 












































































Figure 3.1.9. The effect of liraglutide pre-treatment on the viability of SH-SY5Y cells treated with 
200 M hydrogen peroxide. Cells were grown to 60% confluence and then pre-treated for 24 h with 
75, 150, 750 nM liraglutide in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 200 M hydrogen peroxide and 75, 150, and 750 nM  fresh liraglutide in 
UltraMEM were added to the cells. Following a further 48 h culture period, an MTS cell viability was 
performed as described in the Materials and Methods section. Results are expressed as a percentage 
of the control viability at each liraglutide concentration and are means ± S.D. (n=3). *, significant at p 









































3.1.2.2. Exendin-4 and hydrogen peroxide treatment 
The ability of a second GLP-1 analogue, exendin-4, to protect against hydrogen 
peroxide-mediated cytotoxicity was also examined. Here, the experiments were 
conducted as described in the preceding section for the liraglutide pre-treatment 
experiments. The effect of the drug against both 300 and 200 M stressor 
concentrations was examined but no protective effect of exendin-4 could be 
demonstrated at the former hydrogen peroxide concentration (Fig. 3.1.10). However, 
at the lower, 200 M, hydrogen peroxide concentration a trend towards a protective 
effect of exendin-4 could be observed (Fig. 3.1.11.). However, this trend could only 









Figure 3.1.10. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
300 M hydrogen peroxide. Cells were grown to 60% confluence and then pre-treated for 24 h with 
2, 20, 100, and 200nM exendin-4 in complete growth medium. Next the cells were washed in situ 
with UltraMEM and then 300 M hydrogen peroxide and 2, 20, 100, and 200 nM fresh exendin-4 in 
UltraMEM were added to the cells. Following a further 48 h culture period, an MTS cell viability was 
performed as described in the Materials and Methods section. Results are expressed as a percentage 
of the control viability at each exendin-4 concentration and are means ± S.D. (n=3). 
Figure 3.1.11. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
200 M hydrogen peroxide. Cells were grown to 60% confluence and then pre-treated for 24 h with 2, 
20, 100, and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 200 M hydrogen peroxide and 2, 20, 100, and200 nM fresh exendin-4 in 
UltraMEM were added to the cells. Following a further 48 h culture period, an MTS cell viability was 
performed as described in the Materials and Methods section. Results are expressed as a percentage 














































































































Figure 3.1.12. The effect of cobalt chloride on SH-SY5Y cell viability in the presence of UltraMEM. 
Cells were grown to 80% confluence, washed in situ with UltraMEM and then 0, 50, 100, 200, 300, 
500, and 1000 M cobalt chloride in UltraMEM was added to the cells. Following a further 24 h 
culture period, an MTS cell viability was performed as described in the Materials and Methods 
section. Results are expressed as a percentage of the control viability and are means ± S.D. (n=3). 
 
 
3.1.3. GLP-1 analogues and cobalt chloride treatment. 
Cobalt chloride was used to mimic hypoxia as it has previously been shown to 
enhance expression of hypoxia-induced factor-1a (HIF-1a) (Fukuda et al., 2002). As 
with the hydrogen peroxide previously, a toxicity curve for this stressor was first 
generated using SH-SY5Y cells. To this end, cells were grown until they were 80% 
confluent and then washed in situ with UltraMEM before replacing this with fresh 
UltraMEM containing a range of cobalt chloride concentrations (0-1000 M). The 
cells were then cultured overnight before conducting an MTS assay (see Materials 
and Methods section). The results (Fig. 3.1.12.) show that SH-SY5Y were killed in a 
dose-dependent fashion by cobalt chloride up to a concentration of 300 M after 
which the level of viability remained fairly constant. Consequently, it was decided 
that concentrations between 50 μM and 300 μM would be used in further 











Figure 3.1.13. The effect of liraglutide pre-treatment on the viability of SH-SY5Y cells treated with 
200 M cobalt chloride. Cells were grown to 60% confluence and then pre-treated for 24 h with t75, 
150, 300, and 750 nM liraglutide in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 200 M cobalt chloride and fresh 75, 150, 300, and 750 nM liraglutide in 
UltraMEM were added to the cells. Following a further 48 h culture period, an MTS cell viability was 
performed as described in the Materials and Methods section. Results are expressed as a percentage 




























3.1.3.1. Liraglutide and cobalt chloride treatment 
Having determined the appropriate concentrations of cobalt chloride to use in 
the preceding section, the ability of liraglutide to protect against these stressor 
concentrations was examined. Note that all of these experiments incorporated a pre-
treatment step with the GLP-1 analogue. Liraglutide was only tested against a single 
(200 M) cobalt chloride concentration but the results (Fig. 3.1.13.) clearly showed a 

























Figure 3.1.14. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
100 M cobalt chloride. Cells were grown to 60% confluence and then pre-treated for 24 h with 2, 
20, 100, and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 100 M cobalt chloride and fresh 2, 20, 100, and 200 nM exendin-4 in UltraMEM 
were added to the cells. Following a further 48 h culture period, an MTS cell viability was performed 
as described in the Materials and Methods section. Results are expressed as a percentage of the 




























3.1.3.2. Exendin-4 and cobalt chloride treatment 
The ability of exendin-4 to protect against cobalt chloride-induced cytotoxicity 
(this time 50 and 100 M) was also examined in the same manner. Lower 
concentrations of the stressor were used in comparison to those used for treatment 
with Liraglutide in an attempt to increase the effect of exendin-4. However, the 
results using this GLP-1 analogue failed to show any protective effect against the 
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Figure 3.1.15. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
50 M cobalt chloride. Cells were grown to 60% confluence and then pre-treated for 24 h with 2, 20, 
100, and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 50 M cobalt chloride and 2, 20, 100, and 200 nM fresh exendin-4 in UltraMEM 
were added to the cells. Following a further 48 h culture period, an MTS cell viability was performed 
as described in the Materials and Methods section. Results are expressed as a percentage of the 



































3.1.4.  GLP-1 analogues and methylglyoxal treatment 
Methylglyoxal (MG) is cytotoxic due to its induction of endoplasmic stress-associated 
reactive oxygen species and associated mitochondrial dysfunction (Palsamy et al., 
2014, Angeloni et al., 2014). In the current study, SH-SY5Y cells were initially exposed 
to a range of MG concentrations for 24 h and subsequently subjected to an MTS 
assay in order to determine the appropriate stressor concentrations to use in 
subsequent GLP-1 analogue experiments. The results (Fig. 3.1.16) showed an 
intermediate level of cell death of approximately 60-65% at the 2000 μM 
concentration of MG, with approximately 90% and 5-10% at the 2500 μM and 1500 
μM concentrations, respectively. From these results it was determined that MG 
concentrations of 2000 and 1750 M would subsequently be used to examine any 



































Figure 3.1.16. The effect of methylglyoxal on SH-SY5Y cell viability in the presence of UltraMEM. 
Cells were grown to 80% confluence, washed in situ with UltraMEM and then 0, 1200, 1500, 2000, 
and 2500 M methylglyoxal in UltraMEM was added to the cells. Following a further 24 h culture 
period, an MTS cell viability was performed as described in the Materials and Methods section. 










Only the effect of exendin-4 and not liraglutide was tested in relation to MG 
treatment of SH-SY5Y cells. Note also that here the pre-treatment and treatment 
steps were reduced to 6 and 17 h, respectively, such that they were more in line with 
a previous publication (Sharma et al., 2014) in which the effect of MG and a GLP-1 
analogue on SH-SY5Y cells had been investigated. When the effect of exendin-4 was 
investigated in relation to 2000 M MG the results (Fig. 3.1.17.) showed little 
protective effect of the GLP-1 analogue although, at the lowest exendin-4 
concentration (2 nM) there did appear to be a slight but significant effect. However, 
it is notable that this effect was evident regardless of the presence of MG and so is 
unlikely to represent a protective effect. Furthermore, no protective effect of 
exendin-4 was observed when it was tested against a lower MG concentration of 





Figure 3.1.17. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
2000 M methylglyoxal. Cells were grown to 90% confluence and then pre-treated for 6 h with 2, 20, 
100, and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 2000 M methylglyoxal and 2, 20, 100, and 200 nM fresh exendin-4 in UltraMEM 
were added to the cells. Following a further 17 h culture period, an MTS cell viability was performed 
as described in the Materials and Methods section. Results are expressed as a percentage of the 
control viability at each exendin-4 concentration and are means ± S.D. (n=3). *, significant at p = 0.05. 
 
Figure 3.1.18. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
1750 M methylglyoxal. Cells were grown to 90% confluence and then pre-treated for 6 h with 2, 20, 
100, and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 1750 M methylglyoxal and 2, 20, 100, and 200 nM fresh exendin-4 in UltraMEM 
were added to the cells. Following a further 17 h culture period, an MTS cell viability was performed 
as described in the Materials and Methods section. Results are expressed as a percentage of the 














































































































Figure 3.1.19. The effect of thapsigargin on SH-SY5Y cell viability in the presence of UltraMEM. Cells 
were grown to 80% confluence, washed in situ with UltraMEM and then 0, 0.01, 0.1, 1, 10, and 100 
M thapsigargin in UltraMEM was added to the cells. Following a further 24 h culture period, an MTS 
cell viability was performed as described in the Materials and Methods section. Results are expressed 
as a percentage of the control viability and are means ± S.D. (n=3). 
 
3.1.5. GLP-1 analogues and thapsigargin treatment 
Thapsigargin (TG), an endoplasmic reticulum stressor (Stutzbach et al., 2013) 
was used as it has been shown to cause ER stress which correlates with amyloid-β 
production in Retinal Ganglion Cells (RGC) (Liu et al., 2014). In the current study, 
suitable concentrations of TG were first determined by treating SH-SY5Y cells for 24 h 
in the presence of the stressor and then conducting an MTS assay. The results (Fig. 
3.1.19.) show that there was a dose-dependent increase in cell death between TG 
concentrations of 0-100 M. From these data TG concentrations of 10 and 100 M 
were chosen for subsequent GLP-1 analogue experiments. 
 
 
Next, the ability of exendin-4 to protect SH-SY5Y cells against thapsigargin-
induced cytotoxicity was examined. Initially, the GLP-1 analogue showed no 
protective effect against a 100 M stressor concentration (Fig. 3.1.20.). However, 
when a lower (10 M) thapsigargin concentration was used, there was a significant 
protective effect of exendin-4 (at 200 nM) against the stressor (Fig. 3.1.21.).  
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Figure 3.1.20. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
100 M thapsigargin. Cells were grown to 90% confluence and then pre-treated for 6 h with 2, 20, 
100, and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 100 M thapsigargin and 2, 20, 100, and 200 nM fresh exendin-4 in UltraMEM 
were added to the cells. Following a further 17 h culture period, an MTS cell viability was performed 
as described in the Materials and Methods section. Results are expressed as a percentage of the 
control viability at each exendin-4 concentration and are means ± S.D. (n=3). 
Figure 3.1.21. The effect of exendin-4 pre-treatment on the viability of SH-SY5Y cells treated with 
10 M thapsigargin. Cells were grown to 90% confluence and then pre-treated for 6 h with 2, 20, 100, 
and 200 nM exendin-4 in complete growth medium. Next the cells were washed in situ with 
UltraMEM and then 10 M thapsigargin and 2, 20, 100, and 200 nM fresh exendin-4 in UltraMEM 
were added to the cells. Following a further 17 h culture period, an MTS cell viability was performed 
as described in the Materials and Methods section. Results are expressed as a percentage of the 


















































































TG + Exendin-4 
 54 
 
3.2. Expression of ADAM10 and ADAM10 substrates in SH-     
        SY5Y cells 
In the preceding section it was determined that exendin-4 (200 nM) was able 
to protect SH-SY5Y cells against the cytotoxic effects of 10 M thapsigargin. In 
addition, exendin-4 has previously been shown to alter the amount of mature 
ADAM10 in the cell membrane fraction (Ohtake et al., 2014). As such, the current 
study next sought to determine whether the protective effect of exendin-4 observed 
against thapsigargin was linked to changes in the expression/processing of ADAM10 
and some of its key substrates (APP, NLGN-1 and PrP). However, before this could be 
done, it was first necessary to determine the endogenous expression of these 
proteins and, where necessary, generate stable transfectants over-expressing the 
same proteins. 
 
3.2.1. Detection of endogenous and over-expressed ADAM10. 
In order to characterise endogenous expression of ADAM10 in SH-SY5Y cells, cultures 
were grown to confluence in T75 flasks and then lysates were prepared, equalized 
for protein concentration and subjected to PAGE and subsequent immunoblotting 
with an anti-ADAM10 C-terminal antibody as described in the Materials and Methods 
section. The results (Fig. 3.2.1.) showed that ADAM10, in addition to some non-
specific bands, was detected as bands of approximately 97 and 66 kDa most likely 








3.2.1. Endogenous ADAM10 expression. 
As the exposure times required in order to detect endogenous ADAM10 were 
extensive it was decided also to generate stable ADAM10 over-expressing SH-SY5Y 
transfectants. To this end, cells were stably transfected with the pIRESneo-ADAM10 
plasmid or empty vector alone (mock transfectants) as described in the Materials and 
Methods section. Cell lysates were subsequently prepared from both mock- and 
ADAM-10 stable transfectants and once more immunoblotted with the anti-ADAM10 
C-terminal antibody. The results (Fig. 3.2.2.) show the detection of a band at 
approximately 97 kDa that was more intense in the ADAM10- than the mock-
transfectant cell lysates. No increase in a band corresponding to the mature form of 
ADAM10 was detected. However, interestingly, there was also a very prominent 
band at around 14.4 kDa in the ADAM10-transfected cell lysates possibly 
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Figure 3.2.1. Immunodetection of endogenous ADAM10 in SH-SY5Y cell lysates. Three independent 
cell cultures (lanes 1-3) were grown to confluence and lysates prepared, equalized in terms of protein 
and subjected to PAGE and immunoblotting as described in the Materials and Methods section. A. 
Immunodetection using an anti-ADAM10 C-terminal antibody. B. Immunodetection using an anti-
actin antibody. Dashed lines show where non-adjacent lanes form the same immunoblot were spliced 
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3.2.2. Detection of endogenous and over-expressed APP. 
 APP has previously been shown to be a substrate for ADAM10 by many 
groups (Gough, Parr-Sturgess and Parkin, 2011, Postina et al., 2004).  In the current 
study, the lysate samples used in Fig.3.2.1. were immunoblotted using an anti-APP C-
terminal antibody in order to assess endogenous expression of APP. The results (Fig. 
3.2.3.) show that APP was detected as a number of bands around 110 kDa consistent 
with there being multiple APP glycoforms and isoforms in SH-SY5Y cells (Delvaux et 
al., 2013). In addition, SH-SY5Y cells were stably transfected with an IREShyg- APP695 
plasmid as described in the Materials and Methods section. 
Figure 3.2.2. Immunodetection of over-expressed ADAM10 in SH-SY5Y cell lysates. Three 
independent cell cultures of mock- (lanes 1,3 and 5) and ADAM10-transfected (lanes 2, 4 and 6) cells 
were grown to confluence and lysates prepared, equalized in terms of protein and subjected to PAGE 
and immunoblotting as described in the Materials and Methods section. A. Immunodetection using 
an anti-ADAM10 C-terminal antibody. B. Immunodetection using an anti-ADAM10 C-terminal 
antibody and a lower acrylamide concentration gel in order to show the putative ADAM10-CTF (C-






















Independent T75 flask cultures of both mock- and APP695- transfected cells 
were grown to confluence and then washed in situ with UltraMEM before replacing 
the wash with 10 ml of the same medium and incubating the cells for a further 24 h. 
The conditioned medium was then collected and processed and cell lysates prepared 
as described in the Materials and Methods section. The lysates were then 
immunoblotted with an anti-APP C-terminal antibody. The results (Fig. 3.2.4.) clearly 
show that APP695 was successfully over-expressed with the protein being so 
abundant that, at the level of exposure used, endogenous APP was not even 





Figure 3.2.3. Immunodetection of endogenous APP in SH-SY5Y cell lysates. Three independent cell 
cultures (lanes 1-3) were grown to confluence and lysates prepared, equalized in terms of protein and 
subjected to PAGE and immunoblotting as described in the Materials and Methods section using an 
























Next, the 24 h conditioned medium was immunoblotted with antibody 6E10 to 
detect sAPP and an anti-sAPP antibody. The results show that two bands were 
detected in conditioned medium using antibody 6E10 (Fig. 3.2.5A); the bottom band 
corresponded to sAPP695 and the top to a combination of sAPP751/770. Notably, 
the lower band was substantially increased in the APP695-transfected cells showing, 
once again, that the stable transfection had been successful. In contrast, sAPP was 






Figure 3.2.4. Immunodetection of over-expressed APP in SH-SY5Y cell lysates. Three independent 
cell cultures of mock- (lanes 1,3 and 5) and APP695-transfected (lanes 2, 4 and 6) cells were grown to 
confluence and lysates prepared, equalized in terms of protein and subjected to PAGE and 
immunoblotting as described in the Materials and Methods section. A. Immunodetection using an 



























3.2.3. Detection of over-expressed NLGN1. 
 NLGN1 has also previously been shown to be a substrate for ADAM10 (Suzuki 
et al., 2012). In the current study, the endogenous protein could not be detected in 
SH-SY5Y cell lysates and so cells were stably transfected with an pIRESneo-NLGN1 
plasmid as described in the Materials and Methods section. 
Independent T75 flask cultures of both mock- and NLGN1-transfected cells 
were grown to confluence and then then washed in situ with UltraMEM before 
replacing the wash with 10 ml of the same medium and incubating the cells for a 
further 24 h. The conditioned medium was then collected and processed and cell 
lysates prepared as described in the Materials and Methods section. The lysates 
were then immunoblotted with an anti-NLGN1 N-terminal antibody. The results (Fig. 
3.2.6.) showed a band at 110 kDa the intensity of which was enhanced in the NLGN1-
transfected cell lysates consistent with previously reported sizes for the protein 
(Peixoto et al., 2012). 
Figure 3.2.5. Immunodetection of over-expressed APP fragments in SH-SY5Y cell conditioned 
medium. Three independent cell cultures of mock- (lanes 1,3 and 5) and APP695-transfected (lanes 2, 
4 and 6) cells were grown to confluence and conditioned medium was prepared and subjected to 
PAGE and immunoblotting as described in the Materials and Methods section. A. Immunodetection 






























Next, the 24 h conditioned medium was immunoblotted with the same anti-
NLGN1 N-terminal. The results (Fig. 3.2.7.) showed a very intense band again at 
around 110 kDa in only the NLGN1-transfected cell lysates proving that the stable 












Figure 3.2.6. Immunodetection of over-expressed NLGN1 in SH-SY5Y cell lysates. Three independent 
cell cultures of mock- (lanes 1,3 and 5) and NLGN1-transfected (lanes 2, 4 and 6) cells were grown to 
confluence and lysates prepared, equalized in terms of protein and subjected to PAGE and 
immunoblotting as described in the Materials and Methods section. A. Immunodetection using an 
anti-NLGN1 N-terminal antibody. B. Immunodetection using an anti-actin antibody.  
 
Figure 3.2.7. Immunodetection of over-expressed NLGN1 fragments in SH-SY5Y cell conditioned 
medium. Three independent cell cultures of mock- (lanes 1,3 and 5) and NLGN1-transfected (lanes 2, 
4 and 6) cells were grown to confluence and conditioned medium was prepared and subjected to 
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3.2.4. Detection of endogenous and over-expressed PrP. 
 PrP was originally shown to be shed from the cell surface by the action of 
both a phospholipase and an ADAM-like activity in a ‘dual shedding’ manner (Parkin 
et al., 2004). It was subsequently shown that ADAM10 was the zinc 
metalloproteinase responsible for this shedding activity (Taylor et al., 2009). In the 
current study, endogenous PrP was detected in cell lysates using the SAF32 antibody 
as a typical smear centred around 35 kDa (Fig. 3.2.8A.). Minor amounts of the 
endogenous protein were also detected in conditioned medium using the same 


















Figure 3.2.8. Immunodetection of endogenous PrP in SH-SY5Y cell lysates and conditioned medium. 
Three independent cell cultures (lanes 1-3) were grown to confluence and incubated for 24 h with 
UltraMEM. Cell lysates and conditioned medium samples were then prepared as detailed in the 
Materials and Methods section. A. Immunodetection of PrP in cell lysates using SAF32. B. 


















 As only very low levels of endogenous PrP were detected in conditioned 
medium, stable transfectants were also generated using a pIRESneo-PrP plasmid as 
described in the Materials and Methods section.  
Independent T75 flask cultures of both mock- and PrP-transfected cells were grown 
to confluence and then washed in situ with UltraMEM before replacing the wash 
with 10 ml of the same medium and incubating the cells for a further 24 h. The 
conditioned medium was then collected and processed and cell lysates prepared as 
described in the Materials and Methods section. The lysates were then 
immunoblotted with the SAF32 antibody. The results (Fig. 3.2.9.) clearly show that 
PrP was successfully over-expressed with the protein being so abundant that, at the 









Next the conditioned medium was also immunoblotted with SAF32 and the results 
(Fig. 3.2.10.) clearly shed that, not only was PrP successfully over-expressed, it was 
effectively shed into the conditioned medium of cells. 
Figure 3.2.9. Immunodetection of over-expressed PrP in SH-SY5Y cell lysates. Three independent cell 
cultures of mock- (lanes 1,3 and 5) and PrP-transfected (lanes 2, 4 and 6) cells were grown to 
confluence and lysates prepared, equalized in terms of protein and subjected to PAGE and 
immunoblotting as described in the Materials and Methods section. A. Immunodetection using 






















3.3. The effects of exendin-4 and thapsigargin on the  
        expression and proteolysis of ADAM10 and its substrates. 
This study determined that exendin-4 (200 nM) protected SH-SY5Y cells against 
thapsigargin-mediated toxicity (section 3.1.5.). Having generated stable transfectants 
over-expressing ADAM10 or its key substrates (section 3.2.), the next step was to 
examine whether thapsigargin treatment in the absence or presence of exendin-4 
altered the expression/proteolysis of the over-expressed proteins. 
 
3.3.1. The effect of exendin-4 and thapsigargin on the expression and proteolytic  
           maturation of over-expressed ADAM10  
SH-SY5Y-ADAM10 stable transfectants were grown to 90% confluence in T75 flasks 
and then pre-treated with 200 nM exendin-4 for 6 h before further incubating the 
cells in the presence of 10 M thapsigargin and/or fresh exendin-4 for a further 17 h. 
The cells were then harvested, processed and immunoblotted with anti-ADAM10 C-
terminal antibody as described in the Materials and Methods section. The results 
(Fig. 3.3.1.A) suggest that treatment with thapsigargin decreases mature ADAM10 
and increases immature ADAM10, with figure 3.3.1.C confirming that all protein 
Figure 3.2.10. Immunodetection of over-expressed PrP fragments in SH-SY5Y cell conditioned 
medium. Three independent cell cultures of mock- (lanes 1,3 and 5) and PrP-transfected (lanes 2, 4 
and 6) cells were grown to confluence and conditioned medium was prepared and subjected to PAGE 




levels were equal between samples. Following image processing analysis, figure 
3.3.1.B shows a significant increase in the levels of immature ADAM10 in response to 
thapsigargin treatment with a concomitant decrease in levels of the proteolytically 
mature form of the enzyme. Exendin-4, in the presence of thapsigargin, had no 






Figure 3.3.1. The effect of exendin-4 and thapsigargin treatments on ADAM10 expression and 
proteolytic maturation in SH-SY5Y-ADAM10 cells. Cells were grown to confluence in T75 flasks 
before being pre-treated for 6 h with 200 nM exendin-4 in complete growth medium. Next the cells 
were washed in situ with 10 ml UltraMEM before adding a fresh 10 ml of the same medium 
containing the relevant treatment (lane 1, control; lane 2, exendin-4; lane 3, thapsigargin (10 M); 
lane 4, exendin-4 + thapsigargin (10 M). The cells were then cultured for a further 17 h before 
harvesting them, preparing cell lysates and immunoblotting with A. Anti-ADAM10 C-terminal 
antibody and C. Anti-actin antibody. Representative blots are shown for each experiment, which was 
repeated in triplicate and multiple ADAM10 blots were quantified and the relative levels of the 
immature and proteolytically mature protein are shown in B. Results are means ± S.D. (n=3). **, 
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3.3.2. The effect of exendin-4 and thapsigargin on the expression and proteolytic  
           shedding of endogenous APP 
Untransfected SH-SY5Y cells were treated with exendin-4 and/or thapsigargin as 
described in the preceding section and cells and conditioned medium samples were 
harvested and processed as described in the Materials and Methods section. Initially, 
the lysates were immunoblotted with the anti-APP C-terminal antibody and the 
results (Fig. 3.3.2.) show that thapsigargin treatment reduced APP holoprotein levels 
by approximately 50% relative to the control cultures. Interestingly, exendin-4 was 





Figure 3.3.2. The effect of exendin-4 and thapsigargin treatments on endogenous APP expression in 
untransfected SH-SY5Y cells. Cells were grown to confluence in T75 flasks before pre-treatment for 6 h 
with 200 nM exendin-4 in complete growth medium. The cells were washed in situ with 10 ml UltraMEM 
before adding a fresh 10 ml of the same medium containing the relevant treatment (lane 1, control; lane 
2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 + thapsigargin (10 M). The cells were 
cultured for a further 17 h before harvesting, preparing cell lysates and immunoblotting with A. Anti-APP 
C-terminal antibody and C. Anti-actin antibody. Representative blots are shown for each experiment 
which was repeated in triplicate and multiple APP blots were quantified and the relative levels of the 
protein are shown in B. Results are means ± S.D. (n=3). *, significant at p = 0.05; **, significant at p = 




The conditioned medium samples were then immunoblotted with antibody 6E10 to 
detect sAPP and the anti-sAPP antibody. The results (Fig. 3.3.3.) show that sAPP 
was significantly decreased and sAPP was dramatically decreased in the conditioned 
medium from thapsigargin-treated cells; though this could not be deemed significant 
as n=1 and therefore a statistical 1 tailed, type 2 could not be performed. However, 
exendin-4 either on its own or in the presence of thapsigargin had no additional 






Figure 3.3.3. The effect of exendin-4 and thapsigargin treatments on the levels of soluble APP in 
conditioned medium from untransfected SH-SY5Y cells. Cells were grown to confluence in T75 flasks 
before pre-treatment for 6 h with 200 nM exendin-4 in complete growth medium. The cells were 
washed in situ with 10 ml UltraMEM before adding a fresh 10 ml of the same medium containing the 
relevant treatment (lane 1, control; lane 2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 
+ thapsigargin (10 M). The cells were cultured for a further 17 h before harvesting the conditioned 
medium, processing it as described in the Materials and Methods section and immunoblotting with A. 
Antibody 6E10 and B. Anti-sAPP antibody. Multiple immunoblots were quantified and the relative 
amounts of each APP fragment are displayed graphically underneath the corresponding immunoblot. 
Results are means ± S.D. (n=3 for sAPP and n=1 for sAPP). *, significant at p = 0.05; **, significant 
at p = 0.01. 
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3.3.3. The effect of exendin-4 and thapsigargin on the expression and proteolytic  
           shedding of over-expressed APP695 
The experiments described in the preceding section were also performed 
using APP695 over-expressing SH-SY5Y cells. The results from these latter experiments 
(Fig. 3.3.4.) showed that thapsigargin enhanced the expression of APP in these cells, 
both of which were significant at the p = 0.05 threshold. However, exendin-4 had no 




Figure 3.3.4. The effect of exendin-4 and thapsigargin treatments on APP expression in SH-SY5Y-
APP695 cells. Cells were grown to confluence in T75 flasks before pre-treatment for 6 h with 200 nM 
exendin-4 in complete growth medium. The cells were washed in situ with 10 ml UltraMEM before 
adding a fresh 10 ml of the same medium containing the relevant treatment (lane 1, control; lane 2, 
exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 + thapsigargin (10 M). The cells were then  
cultured for a further 17 h before harvesting, preparing cell lysates and immunoblotting with A. Anti-
APP C-terminal antibody and C. Anti-actin antibody. Representative blots are shown for each 
experiment which was repeated in triplicate and multiple APP blots were quantified and the relative 















1    2   3     4
sAPPsAPP



























10 M TG 10 M TG 

























10 M TG 10 M TG 
+ 200 nM 
Exendin-4
Next the conditioned medium from these cells was immunoblotted with 
antibody 6E10 and anti-sAPP antibody. The results (Fig. 3.3.5A.) showed that 
thapsigargin alone had no effect on sAPP generation but that exendin-4, when 
added in the presence of thapsigargin, resulted in a significant increase in sAPP 
shedding. In contrast, neither thapsigargin or exendin-4 had any significant effect of 





Figure 3.3.5. The effect of exendin-4 and thapsigargin treatments on the levels of soluble APP in 
conditioned medium from SH-SY5Y-APP695 cells. Cells were grown to confluence in T75 flasks before 
pre-treatment for 6 h with 200 nM exendin-4 in complete growth medium. The cells were washed in 
situ with 10 ml UltraMEM before adding a fresh 10 ml of the same medium containing the relevant 
treatment (lane 1, control; lane 2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 + 
thapsigargin (10 M). The cells were cultured for a further 17 h before harvesting the conditioned 
medium, processing it as described in the Materials and Methods section and immunoblotting with A. 
Antibody 6E10 and B. Anti-sAPP antibody. Multiple immunoblots were quantified and the relative 
amounts of each APP fragment are displayed graphically underneath the corresponding immunoblot. 




3.3.4. The effect of exendin-4 and thapsigargin on the expression and proteolytic  
           shedding of over-expressed NLGN1 
The experiments described in preceding sections were again repeated but this time 
using SH-SY5Y-NLGN1 stable transfectants. The results (Fig. 3.3.6.) showed a 
significant decrease of NLGN1 expression in cells treated with thapsigargin and 






Figure 3.3.6. The effect of exendin-4 and thapsigargin treatments on NLGN1 expression in SH-SY5Y-
NLGN1 cells. Cells were grown to confluence in T75 flasks before being pre-treated for 6 h with 200 
nM exendin-4 in complete growth medium. Next the cells were washed in situ with 10 ml UltraMEM 
before adding a fresh 10 ml of the same medium containing the relevant treatment (lane 1, control; 
lane 2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 + thapsigargin (10 M). The cells 
were then cultured for a further 17 h before harvesting them, preparing cell lysates and 
immunoblotting with A. Anti-NLGN1 N-terminal antibody and C. Anti-actin antibody. Representative 
blots are shown for each experiment which was repeated in triplicate and multiple NLGN1 blots were 
quantified and the relative levels of the protein are shown in B. Results are means ± S.D. *, significant 




Conditioned medium samples from the same experiment were also immunoblotted 
using the anti-NLGN1 N-terminal antibody and the results (Fig. 3.3.7.) show that, 
whilst thapsigargin alone did not alter shedding of NLGN1 into conditioned medium 
in comparison to the control, the co-treatment of thapsigargin-treated cells with 










Figure 3.3.7. The effect of exendin-4 and thapsigargin treatments on the levels of soluble NLGN1 in 
conditioned medium from SH-SY5Y-NLGN1 cells. Cells were grown to confluence in T75 flasks before 
pre-treatment for 6 h with 200 nM exendin-4 in complete growth medium. The cells were washed in 
situ with 10 ml UltraMEM before adding a fresh 10 ml of the same medium containing the relevant 
treatment (lane 1, control; lane 2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 + 
thapsigargin (10 M). The cells were cultured for a further 17 h before harvesting the conditioned 
medium, processing it as described in the Materials and Methods section and immunoblotting with 
an anti-NLGN1 N-terminal antibody. Multiple immunoblots were quantified and the relative amounts 





3.3.5. The effect of exendin-4 and thapsigargin on the expression and proteolytic  
           shedding of over-expressed PrP 
Finally, the experiments described in preceding sections were repeated but 
using SH-SY5Y-PrP stable transfectants. The results (Fig. 3.3.8.) showed that 
thapsigargin, alone or in the presence of exendin-4 dramatically enhanced levels of 
PrP in cell lysates. Exendin-4, in contrast had no effect on PrP expression levels. 
 
  
Figure 3.3.8. The effect of exendin-4 and thapsigargin treatments on PrP expression in SH-SY5Y-PrP 
cells. Cells were grown to confluence in T75 flasks before being pre-treated for 6 h with 200 nM 
exendin-4 in complete growth medium. Next the cells were washed in situ with 10 ml UltraMEM 
before adding a fresh 10 ml of the same medium containing the relevant treatment (lane 1, control; 
lane 2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 + thapsigargin (10 M). The cells 
were then cultured for a further 17 h before harvesting them, preparing cell lysates and 
immunoblotting with A. SAF32 antibody and C. Anti-actin antibody. Representative blots are shown 
for each experiment which was repeated in triplicate and multiple SAF32 blots were quantified and 
the relative levels of the protein are shown in B. Results are means ± S.D. **, significant at p = 0.01; 
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 Next, the conditioned medium from the same experiments was 
immunoblotted with the SAF32 antibody in order to detect shed PrP. The results (Fig. 
3.3.9.) suggest that thapsigargin enhanced PrP shedding slightly, whilst treatment of 
cells with exendin-4 enhanced shedding, however none of these increases were 
significant. Interestingly, the co-treatment of thapsigargin and exendin-4  appeared 











Figure 3.3.9. The effect of exendin-4 and thapsigargin treatments on the levels of soluble PrP in 
conditioned medium from SH-SY5Y-PrP cells. Cells were grown to confluence in T75 flasks before 
being pre-treated for 6 h with 200 nM exendin-4 in complete growth medium. Next the cells were 
washed in situ with 10 ml UltraMEM before adding a fresh 10 ml of the same medium containing the 
relevant treatment (lane 1, control; lane 2, exendin-4; lane 3, thapsigargin (10 M); lane 4, exendin-4 
+ thapsigargin (10 M). The cells were then cultured for a further 17 h before harvesting the 
conditioned medium, processing it as described in the Materials and Methods section and 
immunoblotting with the SAF32 antibody. Multiple immunoblots were quantified and the relative 






3.4. Summary.  
            The purpose of this study was to investigate the potential protective effects 
of GLP-1 analogues against various cell stressors and to investigate their effects on 
the expression and proteolysis of ADAM10 and its substrates. 
 In terms of cell viability, hydrogen peroxide was found to be cytotoxic in a 
dose-dependent fashion in the concentration range 0-1000 M. The protective effect 
of liraglutide was limited to 200 M hydrogen peroxide; with higher stressor 
concentrations there was no protective effect. In contrast, exendin-4 exhibited very 
/little by the way of protection against hydrogen peroxide-mediated cytotoxicity. 
Cobalt chloride was also found to be cytotoxic in a dose-dependent fashion in the 
concentration range of 0-1000 M. Again, liraglutide proved to have the greater 
protective effect enhancing cell viability in the presence of 200 M cobalt chloride at 
all the concentrations tested (75, 150, 300 and 750 nM). Exendin-4 was not 
protective against cobalt chloride-induced cytotoxicity. Methylglyoxal was cytotoxic 
in a dose-dependent fashion over a concentration range of 0-2500 M. The 
protective effects of liraglutide were not tested against this stressor, partly due to 
concerns surrounding the drug’s integrity but also because the link between exendin-
4 and ADAM10 shifted the focus onto this GLP-1; however exendin-4 was and 
showed minimal protective effects. Finally, in terms of cell viability, thapsigargin was 
shown to be cytotoxic in a dose-dependent fashion between 0 and 100 M. Again, 
liraglutide was not tested against this stressor but exendin-4 (200 nM) was protective 
against 10 M but not 100 M thapsigargin. 
 The effects of exendin-4 (200 nM) and/or thapsigargin (10 M) treatment on 
the expression and proteolysis of ADAM10 and some of its key substrates were then 
examined. The proteolytic maturation of over-expressed ADAM10 appeared to be 
inhibited by thapsigargin, however exendin-4 was unable to modify this effect.  
In the case of endogenous APP, thapsigargin decreased expression levels, an 
effect that was partially restored by exendin-4. Thapsigargin also decreased the 
generation of both sAPP and sAPP in a manner that was not affected by co-
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incubation with thapsigargin and exendin-4. However, the situation was somewhat 
different when SH-SY5Y-APP695 cells were used. Here, thapsigargin appeared to 
actually enhance APP expression and this corresponded with increased sAPP 
shedding upon co-treatment with both the stressor and the drug, but not sAPP 
shedding. No additional significant effects were observed when cells were treated 
with exendin-4 in the absence or presence of thapsigargin. 
In SH-SY5Y-NLGN1 cells, the combination of thapsigargin and exendin-4 
significantly decreased the expression of NLGN-1, in comparison to the effects of 
thapsigargin alone. Similarly, thapsigargin alone did not enhance NLGN-1 shedding 
but co-treatment with both thapsigargin and exendin-4 did enhance shedding.  
Finally, thapsigargin caused a dramatic accumulation of PrP in the lysates of 
SH-SY5Y-PrP cells. No increase in the shedding of PrP was evident from thapsigargin-
treated cells  and although there appeared to be PrP shedding caused by treatment 
with exendin-4 alone, this was not significant. 
In summary, the effects of thapsigargin and exendin-4 on the expression of 
ADAM10 and its substrates were diverse and differed depending on whether 
proteins were under endogenous promoter control or stably over-expressed. 
Certainly, whilst thapsigargin alone had dramatic effects on the expression of some 
proteins there appeared to be no consistent link between exendin-4 treatment and 
























4.1.  Introduction.  
Previous research has investigated the potential use of GLP-1 analogues in the 
treatment of neurodegenerative diseases (Parthsarathy, V. and Hölscher, C., 2013, 
Chen et al., 2012) and some of these compounds are currently in clinical trials 
because of their apparent neuroprotective properties (NCT01255163- A Pilot 
Clinical Trial of Exendin-4 in Alzheimer’s Disease, NCT03439943 – Study to 
Evaluate the Effect of Lixisenatide in Patient with Parkinson’s Disease) 
(Clinicaltrials.gov, 2018). In addition, one of these compounds, exendin-4, has been 
shown to increase levels of the secretase, ADAM10 in the cell membrane fraction 
and to alter APP processing (Ohtake et al., 2014). 
The aims of the current project were to determine whether GLP-1 analogues 
were able to protect human neuroblastoma, SH-SY5Y, cells against toxic insults 
related to neurodegenerative conditions and to investigate whether any such 
protective effects were linked to the altered expression/proteolytic maturation of 
ADAM10 and the proteolysis of some of the enzyme's key substrates. 
 
4.2.  The protective effects of GLP-1R agonists against stressors. 
4.2.1. Liraglutide 
 In the current study, liraglutide showed minimal effect against cytotoxicity 
mediated by hydrogen peroxide or cobalt chloride even when cells were pre-treated 
with the drug before adding the stressors. Some protection of the drug against 
hydrogen peroxide and cobalt chloride at a concentration of 200 M was evident 
(Fig. 3.1.9, Fig 3.1.13). Liraglutide has previously been shown to enhance neuronal 
numbers in the brains of APPswe/PS1E9 mice (Parthsarathy, V. and Hölscher, C., 2013)  
although it is notable that, in this study, the drug was administered once daily for 7 
days as opposed to the much shorter cell culture treatments in the current study. 
Shimoda et al. (2011) showed that twice daily administration of liraglutide to  BKS.Cg-
+ Leprdb/+ Leprdb/Jcl (db/db) mice for a period of 2 days increased the expression of 
gene products involved in cell proliferation and differentiation and in the inhibition 
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of apoptosis. However, the authors also demonstrated no effect of the drug on gene 
products associated with the cell response to oxidative or ER stress. The same study 
showed that an extended course of liraglutide administration (2 weeks) enhanced 
the expression of these latter gene products again suggesting that prolonged 
exposure to the drug was necessary to alter cellular response to oxidative insult. In 
addition, in a study led by Hansen, it was found that liraglutide also showed no 
neuroprotective effects against varying levels of dopaminergic neuronal loss in the 
rat 6-OHDA lesion model of Parkinson’s Disease (PD) (Hansen et al., 2016).  
 
4.2.2. Exendin-4 
 Like liraglutide, exendin-4 did not have broad ranging protective effects 
against the stressors studied in the current report (there was a slight effect against 
200 M hydrogen peroxide and 10 M thapsigargin (Fig. 1.3.21)). Although these 
results contradict some literature surrounding the protective effects of exendin-4 
(Chen et al., 2012, Perry et al., 2002), Crutchlow et al. (2008) demonstrated that 
exendin-4 was ineffective in both the promotion of -cell proliferation and the 
reduction of-cell death throughout the first 10 days following a syngeneic islet 
transplant in mouse recipients (Crutchlow et al., 2008). Similarly, Fan et al. (2008) 
reported that, although exendin-4 improved blood glucose control in young and old 
C57/DBA mice, this was not correlated with an increase in -cell proliferation. 
Additionally, Chen et al. (2011) showed that, whilst exendin-4 had a therapeutic 
effect on lipopolysaccharides (LPS) induced inflammatory response, it did not 
prevent apoptosis in H9c2 cells.  
 The current study demonstrates that exendin-4 was protective against low 
(10 M) concentrations of the competitive SERCA inhibitor, thapsigargin (Fig. 1.3.21). 
These data corroborate several other studies (Abe et al., 2013, Younce, Burmeister 
and Ayala, 2013). Furthermore, Kim et al. (2012) showed that exendin-4 inhibited 
apoptosis in HIT-T15 -cells treated with glibenclamide. Although glibenclamide is 
predominantly an inhibitor of ATP-sensitive potassium channels, the authors also 
reported a reduction in SERCA2 and SERCA3 mRNA following a 48 h cell treatment 
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with the drug. A similar reduction was observed with TG and, furthermore, SERCA 
levels along with ER calcium uptake, were replenished when the cells were pre-
treated with exendin-4. These observations might explain why, in the current study, 
exendin-4 had a greater protective effect against TG than other stressors in SH-SY5Y 
cells. 
 
4.3.  The effect of exendin-4 on the expression and proteolysis of 
ADAM10 
 In the current study, TG appeared to reduce the serine-protease-mediated 
removal of the prodomain from ADAM10 resulting in an accumulation of the larger 
molecular weight proteolytically immature form of the enzyme with a concomitant 
decrease in the amount of catalytically active proteolytically mature enzyme (Fig. 
3.3.1A and B). As TG is known to induce ER stress (Lytton et al., 1991), this might 
cause retention of ADAM10 in this membrane system and, subsequently, less 
cleavage of the protein in the Golgi by furin and/or prohormone convertase 7 (PC7) 
(Lichtenthaler, 2010).  Another possible explanation could be that the disrupted 
calcium homeostasis caused by TG (Lytton et al., 1991) could affect the calcium-
dependant activities of the afore mentioned proteases.  
The results from this study also demonstrated that in combination with TG, exendin-
4 was unable to reverse the detrimental effects of the stressor, displaying no 
significant effect on the levels of immature ADAM10 and mature ADAM10 (Fig. 
3.3.1A and B). This would suggest that the protective effect against TG may not 
actually result from the increased trafficking and maturation of ADAM10 as first 
hypothesised, but rather involves another mechanism entirely.  
 
4.4.  The effect of exendin-4 on the expression and proteolysis of APP 
 The results from this study (Fig. 3.3.2A and B) demonstrated that TG 
significantly decreased the expression of endogenous APP in SH-SY5Y cells, as well as 
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significantly reduced the shedding of sAPPFig. 3.3.3A). Additionally TG also 
appeared to reduce the shedding of sAPP (Fig. 3.3.3B) although this latter result 
was somewhat limited by lack of experimental repetition. Jung et al. (2015) reported 
that, in 7w-PSML cells (a Chinese Hamster Ovary cell line, stably transfected to 
express wild-type APP and mutant presenilin 1), treatment with calcium ionophore 
A23187 resulted in an intracellular calcium influx not dissimilar to that observed in 
the case of TG-induced ER stress. The authors also reported concomitantly 
enhanced degradation of APP by the ubiquitin-proteasome system (UPS) and 
subsequently impaired generation of both sAPP, and sAPP. It is, therefore, 
possible in the current study that TG promoted UPS-mediated degradation of APP 
and a concomitant decrease in shedding of the protein. It was also notable in the 
current study that exendin-4 partly reversed the TG-mediated reduction in 
endogenous APP levels (Fig. 3.3.2A and B). This might have resulted from the 
previously outlined phenomenon whereby exendin-4 might reverse the effect of 
TG on ER calcium uptake (section 4.2.2). 
 Interestingly, in the current study, the effects of TG and exendin-4 on APP 
expression and proteolysis differed substantially between cells expressing 
endogenous levels of the protein (section 3.3.2.) and stable transfectants over-
expressing APP695 (section 3.3.3.). In the latter cells TG significantly enhanced APP 
expression (Fig. 3.3.4. A and B) and in combination with exendin-4, TG also 
significantly increased shedding of sAPP. Kögel et al. reported that PC12 cells that 
over-expressed wild-type APP actually provided protection against neuronal 
apoptosis induced by two ER stressors; tunicamycin and brefeldin A, in comparison 
to vector-transfected control cell lines PC12 neo O1 and PC12 neo O3 (Kögel et al., 
2003), which could provide a possible explanation for the differences between the 






4.5.  The effect of exendin-4 on the expression and proteolysis of 
NLGN-1 
The combination of treatment with exendin-4 and TG showed a significant decline in 
the expression of NLGN-1 in comparison to TG alone (Fig. 3.3.6). Additionally, the 
combination of treatment with both the stressor and the drug displayed a significant 
increase in the shedding of NLGN-1 in comparison to the stressor alone (Fig. 3.3.7). 
Consequently, the reduction of NLGN-1 after treatment with exendin-4 and TG is 
accounted for by a significant increase in the shedding of NLGN-1 N-terminal 
following the same treatment. This indicates that exendin-4 is able to cleave this 
protein in response to stress, however previous data discussed in this study (section 
4.3) implies that this mechanism does not involve the maturation of ADAM-10. 
Interestingly, Peixoto et al. reported that the proteolytic activity of matrix 
metalloprotease 9 (MMP9) is involved in the cleavage of NLGN-1 (Peixoto et al., 
2012), which could be a possible component in the mechanism enforced by exendin-
4. The authors also described that the Ca2+/calmodulin-dependent protein kinase 
also plays a role in the cleavage of this protein, which is particularly interesting 
considering the apparent calcium homeostasis restorative effect of exendin-4 
reported by studies mentioned in previous sections (4.2.2 and 4.4). 
 
4.6.  The effect of exendin-4 on the expression and proteolysis of PrP 
The results from this study also showed that thapsigargin-induced ER stress 
enhanced the levels of cell-associated PrP (Fig. 3.3.8). In this respect, Déry et al. 
(2013) showed that ER stress, as indicated by increased expression of the ER stress 
marker immunoglobulin heavy chain binding protein BiP, enhanced PrP expression in 
breast cancer tumours. The authors also demonstrated that PrP expression increased 
in MCF-7 cells following 18 h treatment with TG. Furthermore, Orsi et al. (2006) 
demonstrated that ER stress, and in particular TG, increased the levels of cytosolic 
PrP, a form which interestingly retained its N-terminal signal peptide and did not 
display N-glycans or disulphide bonds, suggesting that  it did not enter the ER (Orsi et 
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al. 2006). If the cytosolic PrP in this study is the same or a similar form to that found 
by Orsi et al, it could imply that TG inhibits the trafficking of the protein. Notably the 
increase in cell-associated PrP in the current study did not correlate with enhanced 
shedding of the protein (Fig. 3.3.9). This could be explained by the findings of the 
afore-mentioned study whereby PrP is retained in intracellular components and, 
therefore, not present at the cell surface to be subject to shedding. 
 
4.7.    Limitations 
The main limitation in this study was the uncertainty surrounding the integrity of the 
Liraglutide. The behaviour of the drug in this study contradicted a large amount of 
the literature surrounding its neuroprotective effects in cells, and in particular SH-
SY5Y cells; however, it was not evident as to why. It was speculated that it could have 
been associated with the storage conditions or the origin of the drug, as it was not 
obtained directly from the supplier. To ensure this did not affect the outcomes of this 
study, Liraglutide was not used in later experiments, with the focus shifting to 
exendin-4 instead. Exendin-4 was purchased from the supplier and prepared to 
known concentrations in the laboratory.  
 
4.8.  Conclusions 
 The purpose of this study was to investigate the effects of GLP-1 receptor 
agonists on the protection of SH-SY5Y cells against various stressors related to 
neurodegeneration and, in particular, Alzheimer’s disease. A further aim was to 
investigate whether any such neuroprotection might be associated with altered 
ADAM10 expression/processing and proteolysis of ADAM10 substrates. The results 
from the study found that neither liraglutide nor exendin-4 had major effects in 
terms of protecting SH-SY5Y cells against oxidative stress, hypoxia, or endoplasmic 
reticulum stress. Exendin-4 did show significant protection against thapsigargin-
induced ER stress, however it was demonstrated that this drug was unable to reverse 
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the TG-induced increase of immature ADAM-10, suggesting that its neuroprotective 
properties were not related to ADAM-10 maturation.  
 In regards to ADAM10 substrates, exendin-4 was able to increase endogenous 
APP expression in SH-SY5Y cells in combination with TG, but displayed no significant 
effect on the shedding of the protein. (Fig. 3.3.2, Fig. 3.3.3). In contrast, in APP over-
expressing cells the drug was able to increase the shedding of sAPPwhen the cells 
were co-treated with TG. Similarly, exendin-4 was able to partly restore the shedding 
of NLGN-1 in TG-treated SH-SY5Y cells (Fig. 3.3.7). However, exendin-4 failed to 
restore the shedding of PrP in TG-treated cells (Fig. 3.3.9). 
 In regards to the direction of future research following on from this study, a 
particularly interesting further experiment would be to examine the mechanism of 
how Exendin-4 provides protection against TG in neuronal cells and whether calcium, 
or other metalloproteinases have an involvement. The role of; glial cells, 
inflammation, insulin, and other factors could also be researched, to investigate 
whether they have an effect on APP processing, and whether they have any 
interactions or beneficial relations with GLP-1 receptor agonists.  In future studies it 
might also be pertinent to examine the role of other types of GLP-1 receptor agonists 
on the proteolysis of APP and NLGN-1 in particular. However to conclude this study, 
certainly, in terms of APP and NLGN-1 the enhanced shedding of these proteins in 
TG-treated cells raises the possibility that exendin-4 might have a role to play in the 
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